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1 Introduction 
1.1 Atherosclerosis 
 Pathogenesis of atherosclerosis 1.1.1
Atherosclerosis, a chronic inflammatory disease, causes plaque formation and luminal 
narrowing in large and medium-sized arteries and can lead to ischemia of heart, brain, or 
extremities, resulting in infarction
1-4
. The cardiovascular diseases due to atherosclerosis 
are the leading cause of death in developed countries, although the mortality rates have 
fallen in recent years
5
. The risks of atherosclerosis are considered as interactions between 
genetic and environmental factors, such as high levels of low density lipoprotein (LDL), 
increased blood pressure and diabetes. Under these risk factors, atherosclerotic plaque is 
characterized by endothelial cell activation, lipids accumulation, inflammatory cells 
recruitment, macrophage and foam cell formation, smooth muscle cells (SMCs) 
migration and extracellular matrix deposition in arterial wall
2-4
.  
 
The large and medium-sized arteries has three morphologically layers (Figure 1). The 
intima (innermost and very thin layer) is composed of loose connective tissue 
(extracellular connective tissue matrix, primarily proteoglycans and collagen) and 
covered by a monolayer of endothelial cells on the luminal side. Bounded by internal 
elastic lamina with intima, the media (the middle layer) is consisted of SMCs with 
regular arrangement and some extracellular collagen. The adventitia (outer layer) consists 
connective tissues with few fibroblasts, SMCs, micro vessels, lymphatic vessels and 
nerves
1
. 
 
 
Figure1. The structure of normal 
large artery (Lusis AJ
1
). 
This diagram shows 3 layers of a 
muscular artery. Normal intima is very 
thin (exaggerated in this figure). 
Middle lay maintains vessel elasticity. 
Adventitia consists mainly of 
connective tissues
1
. 
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 Various stages of atherosclerosis 1.1.2
Under hyperlipidemia and systemic inflammation, endothelial cells (ECs) get activated 
and trigger the early plaque formation (known as fatty streak formation). After activation, 
ECs highly express leukocyte adhesion molecules, better for leukocytes rolling, adhesion 
and migration into the intima3, such as vascular cell adhesion molecule-1 (VCAM-1) 
upregulated before leukocyte recruitment to the areas of plaque development
6
. Moreover, 
ECs defect increases vascular permeability facilitating lipid components deposition, 
especially low-density lipoprotein (LDL). Sub-endothelial LDL is oxidized into oxidized 
LDL (oxLDL) and internalized by monocytes in plaque through overexpressed scavenger 
receptors, such as scavenger receptor A (SR-A) and CD367, 8. Lipid-laden monocytes 
transform into macrophages and undergo a series of changes into foam cells that 
ultimately form fatty streaks. Furthermore, oxLDL stimulates ECs to secrete various 
cytokines, which drive inflammatory cells infiltration into intima
7
. The intima becomes 
thicker under fluid dynamics changes at atherosclerosis-prone sites, such as artery 
branching points. Notably, many studies have shown that platelets play important roles in 
this early stage as the first blood cells arriving at a scene of inflammatory endothelium
3, 9
. 
 
Following fatty streak formation, a more complex lesion evolves, which leads to clinical 
complications. The advanced atherosclerosis plaques are characterized by accumulation 
of leukocytes, lipid-laden matrix, apoptotic cells, debris and cholesterol crystals to form a 
necrotic core, which is surrounded by a cap
7
. This cap is called fibrous cap composed of 
collagen-rich extracellular matrix, SMCs, macrophages and T cells. As more extracellular 
matrix components (EMCs) deposition, as plaque growth is promoted by cytokines, like 
interleukin (IL)-1 and 6, and tumor necrosis factor (TNF)-α
10
, and growth factors 
secreted from plaque cells. Eventually, the central core of mature plaques become 
necrotic, and neovascularization
11, 12
. As a result, the arterial lumen narrows (stenosis).   
 
During plaque progression, the matrix-degrading proteases and cytokines secreted from 
plaque cells cause fibrous cap thinning and erosion, which may ultimately lead to plaque 
rupture. Once plaque rupture, various pro-thrombotic materials are exposed to blood, 
such as collagen, plaque debris and tissue factor, which initiate coagulation cascade and 
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A. The early stage 
Endothelial cell activation in systemic 
inflammation leads to early platelet and 
leukocyte adhesion and increased 
endothelial permeability. 
B. The intermediate stage 
Monocytes i into intima and then 
internalize sub-intima accumulated 
lipids, transforming into macrophages 
or foam cells, which ultimately form 
fatty streaks. Continued mononuclear-
cell influx, matrix components 
deposition and SMCs emigration 
promote fibrous proliferation. 
C. The advanced stage 
Apoptosis of macrophages and other 
plaque cells leads to necrotic core 
formation, paralleled with a fibrous cap 
covering on the luminal side that 
consists of matrix and SMCs layer. 
Neovascularization can occur within 
plaque on the adventitial side, and 
leakage of these fragile vessels can lead 
to intra-plaque hemorrhage. 
thrombus formation, resulting in myocardial infarction, stroke or acute limb ischemia
2, 3
 
(Figure 2).    Figure 2: Atherosclerotic stages (Weber et. al
2
). 
 
 
 
  
 
B 
A 
C 
D 
D. The complication 
Thinning and erosion of the fibrous cap 
in unstable plaques, for example, owing 
to matrix degradation by proteases, 
ultimately results in plaque rupture, 
with debris release, coagulation system 
activation and thrombosis in artery. 
This results in arterial occlusion and 
myocardial infarction or stroke. 
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1.2 Neointimal hyperplasia following vascular injury 
Compared to chronic and lipid-induced atherosclerosis, acute mechanical injury also 
leads to arterial narrowing. The vascular stenosis, defined as narrowing more than 50% of 
luminal diameter, is a major clinical pathogen of various cardiovascular events associated 
with arterial ischemia. Current therapeutic approaches to restore blood flow mainly 
include percutaneous transluminal angioplasty (PTA), stenting and bypass surgery, which 
mechanically injury the vessel wall. Although these treatments effectively relieve 
stenosis after operation, the recurrence of stenosis (restenosis) becomes a main clinical 
challenge. The high incidence rate is 25-50% in patients after balloon angioplasty with 
the majority undergoing revascularization within 6 months13, 14. To limit the high rate of 
restenosis after balloon angioplasty, placing a stent into the stenosis was introduced. 
Coronary stenting significantly improved this outcome, as a 10% reduction of restenosis 
rate compared to angioplasty alone
15
. Currently the drug eluting stents are widely 
implemented, which have substantially reduced the restenosis rate. Despite considerable 
development of therapy progress, the mechanisms of restenosis (neointimal hyperplasia) 
remains incompletely understood. 
 
One hypothesis is used to describe some mechanisms that lead to restenosis. In this 
hypothesis, vascular injury causes endothelial denudation, exposure of extracellular 
matrix, platelet adhesion, thrombus formation, leukocytes infiltration
16
, and SMCs 
proliferation, migration and secretion of extracellular matrix
17
. Highly proliferative 
SMCs migrate into intima, undergoing phenotypic modification from contractile to 
synthetic
15
, and this is known as the main character of neointimal hyperplasia. It is drived 
by growth factors, such as transforming growth factor-β and platelet-derived growth 
factor (PDGF)
18
, and cell cycle genes, including upregulated proliferating cell nuclear 
antigen (PCNA) in SMCs to promote cell growth
19
, and highly expressed matrix 
metalloproteinases (MMPs) to facilitate SMCs migration from media to intima
20
. Despite 
this, the inflammatory concept is more and more accepted now.  
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Endothelium plays pivotal roles in suppression of neointimal hyperplasia by inhibition of 
inflammation, thrombus formation and SMCs proliferation and migration
21
. After injury, 
the wound healing process requires endothelial repair. Re-endothelialization was 
classically considered as the migration and proliferation of adjacent endothelial cells to 
cover injured vessel wall. However, mature resident vascular endothelial cells have very 
limited proliferation capacity
22
. Thus, the whole endothelial repair might also dependent 
on circulating bone marrow-derived cells, termed endothelial outgrowth cell (EOCs), 
which can be recruited to the sites of damaged endothelium and differentiate into ECs23. 
EOCs can be derived from circulating endothelial progenitor cells, hematopoietic stem 
cells and myeloid cells
24
. As an endogenous repair mechanism, they also play an 
important role to replace damaged endothelium
25
. Although re-endothelialization protects 
from neointimal formation, dysfunctional endothelial cells are also facilitating leukocytes 
recruitment under inflammatory conditions26. 
Platelets and leukocytes release cytokines, chemokines, vasoactive agents, and growth 
factors, which promote inflammatory response to vessel injury
27
. During neointimal 
formation, activated platelets secrete cytokines and growth factors, which promote 
inflammatory recruitment and SMCs accumulation
26
. Inflammation accompanies with 
neointimal formation after acute vascular injury and thrombus deposition during the 
chronic healing process
28
, which can be characterized by three stages: early thrombotic 
phase, intermediate recruitment phase, and late neointimal proliferation phase
29
. 
In early phase, angioplasty and stenting cause endothelial denudation and dysfunction. 
Consequently, sub-intima exposure activates platelet aggregation, followed by fibrin 
deposition and thrombus formation
30
. In turn, thrombus provokes inflammatory process. 
In intermediate phase, lots of leukocytes are recruited to damaged vessel wall by 
adhesion molecules and chemokines
15
. Firm adhesion and trans-platelet migration of 
leukocytes are mediated by integrins
31
. For example, integrin molecule MAC-1 
(CD11b/CD18) mediates leukocytes firm adhesion to endothelial counter ligands (eg, 
intercellular adhesion molecule-1 [ICAM-1]), to endothelial associated extracellular 
matrix proteins (eg, fibrinogen), or to glycosaminoglycans28, 32, and also to platelets via 
GPIbα
33
. Chemokines recruit leukocytes to vessel wall, which may ultimately lead to 
Introduction 
6 
 
neointimal formation. For example, monocyte chemoattractant protein 1 (MCP-1, CCL2) 
as an arrest chemokine is linked to adherent platelets, thus locally concentrated on the 
denudated endothelium, which can recruit monocytes34. Interestingly, CCL2 is 
upregulated in ECs and SMCs after stenting
35
 and the levels of CCL2 are persistently 
elevated in patients with restenosis
36
. In late phase, neointima is characterized by new 
extracellular matrix accumulation in intima, mainly collagen.  
 
Platelet plays a pivotal role in neointimal formation. Activated platelets release cytokines 
that activate endothelial proliferation, recruit leukocyte and promote SMCs migration 
from the media to the intima, thus it endows complicated functions. Recently, it was 
further characterized in wire-induced carotid injury of apoe
–/– 
mice. After carotid injury, 
CCL5 (RANTES) released from platelets and deposited on ECs in neointimal lesions 
facilitates monocyte migration. Treatment with selective CCR1 and CCR5 antagonist of 
Met-CCL5 clearly reduces macrophage infiltration and neointimal formation, consistent 
with inhibition of CCL5 expression in vivo. Furthermore, it has been found that CCR5 
but not CCR1 appears to be responsible for CCL5-mediated macrophage infiltration and 
neointimal formation
37, 38
.  
 
Junctional adhesion molecule-A (JAM-A) is widely distributed and expressed on platelets, 
erythrocytes, lymphocytes, neutrophils, and monocytes, which has recently been 
implicated in leukocyte recruitment on early atherosclerotic endothelium and promotion 
for neointimal formation
39
. The globally genetic deletion of JAM-A in apolipoprotein e–
deficient (aope–/–) mice significantly reduced neointimal hyperplasia, which was 
associated with a significant decrease of neointimal macrophages. Now we found the 
cell-specific roles of JAM-A in atherosclerosis
40
, indicating that JAM-A functions in 
different cell types might be potentially various in neointimal formation. 
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1.3 Leukocyte migration into the vessel wall 
During whole stages of atherosclerosis (Figure 3), leukocytes migration into vessel wall 
is the main driving force of plaque growth in combination with hyperlipidemia. Lots of 
leukocytes are found in plaques, particularly monocytes (macrophages) and T 
lymphocytes41-43. During attraction of leukocytes, many families of chemoattractant 
cytokines (chemokines) are defined and capable to recruit leukocytes into arterial intima, 
for example, CCL2 overexpressed in plaque can recruit monocytes to the lesion site
44, 45
. 
Targeting molecules involving in leukocyte recruitment would be a novel and beneficial 
therapy for atherosclerosis
46
.  
Leukocyte adhesion and transmigration through vessel wall consists many steps, 
including capture or tethering, slow rolling, arrest, intraluminal crawling and 
transmigration. The first adhesion step is tethering to endothelial cells, which is mediated 
by leukocyte-, platelet-, and endothelial- selectin (CD62-L, -P, and -E) binding to their 
ligands, platelet-selectin glycoprotein ligand-1 (PSGL-1) and other glycosylated ligands. 
Selectins bind to their ligands in a calcium-dependent manner. Leukocyte PSGL-1 
interacting with endothelial E- and P- selection and the same leukocyte L-selectin binding 
to endothelial PSGL-1 enable leukocyte captured and tethering to endothelium. 
Importantly, activated platelets also express P-selectin assisting leukocyte tethering47-49. 
The bonds of selectins with their ligands can be formed or broken dependent on the 
conditions of blood flow. For example, shear stress determinates L-selectin and P-selectin 
interactions with their ligands to support leukocyte adhesion; the tethering cells can 
detach from endothelium when blood flow is stopped
50, 51
, indicating inhibition of low 
shear stress to the interactions. Rapid ligand interaction and dissociation rate of selections 
enable leukocytes tethering or rolling along endothelium under blood shear flow
52
.  
During cell tethering, the leukocytes are rolling along endothelium to search for suitable 
adhesion sites, marked by chemokine gradients and characterized by high cell adhesion 
molecule (CAM) expression. Beside E- and P-selectin assisting leukocyte rolling, 
integrins also mediate leukocyte rolling and further firm adhesion, such as α4β7-integrin–
mucosal vascular addressin cell-adhesion molecule (MADCAM)-1 interaction, very late 
Introduction 
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antigen (VLA)-4–VCAM-1 interaction
53
 and lymphocyte function-associated antigen 
(LFA)-1–intercellular adhesion molecule (ICAM)-1 interaction
54
. Meanwhile cytokines 
activate inflammatory signaling pathways for subsequent steps in leukocyte adhesion 
cascade like adhesion stabilization, crawling and transmigration.  
After rolling step, integrin interaction with adhesion molecular mediates leukocytes arrest 
and firm adhesion on endothelium by increasing integrin affinity. For example, LFA-1 
and VLA-4 change their structures from a bent low affinity to an opened intermediate- or 
high affinity conformation, enabling them to bind their ligands ICAM-1 and VCAM-1 
respectively
55, 56
. Interestingly, activated endothelial cells and platelets can secrete lots of 
chemokines, which are presented on endothelium and interact with G-protein coupled 
receptors (GPCRs) to induce integrin conformation changing57-59. For example, CXC-
chemokine ligand 4 (CXCL4), CXCL5 and CC‑chemokine ligand 5 (CCL5; previously 
known as RANTES) secreted from platelets are deposited on the endothelium to interact 
with GPCRs on passing leukocytes inducing integrin high affinity states to facilitate 
leukocyte arrest
60, 61
. Chemokines trigger GPCRs-related signaling of integrin 
conformation changing, which is referred as inside-out signaling, in contrast to outside-in 
signaling, which is referred as ligand binding to activated integrin for cell adhesion 
strengthening and motility.   
Subsequent to firm adhesion of leukocytes on the endothelium, leukocytes crawl into the 
endothelial junctions or endothelial cell bodys. Leukocytes are stimulated by chemokines 
in intima to migrate through endothelial monolayer. This complicated step involves many 
molecules, such as CD9, CD151, CD81, cytoplasmic molecules like ERM (ezrin, radixin, 
moesin) proteins, and cytoskeletal components like vinculin, α-actin and talin-1. ICAM-1 
binding to integrin ligand MAC-1 can active the signaling cascade, through intracellular 
Ca
2+
, p38 mitogen-activated protein kinase (MAPK) and RAS homologue (RHO) 
GTPase, which can lead contraction of endothelial cells and opening of inter-endothelial 
junctions for leukocyte migration62-65.  
The last step of leukocyte adhesion cascade is leukocyte trans-endothelial migration, 
which takes less time (<2-5 minutes) than migration through the basement membrane 
(>5-15 minutes)66. During migration, the cell-cell junctions are opened transiently to 
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allow leukocyte crossing
67
. Actually, two routes of leukocyte diapedesis across 
endothelium are found: one paracellular route through junctions of adjacent ECs and one 
transcellular route through EC body directly68. However, paracellular pathway might be 
the dominant route, which is mediated by homophilic and heterophilic interactions 
between cell adhesion molecules and integrins. During paracellular migration, the 
junctional cell adhesion molecules can be re-localized away from cell-cell junction to the 
luminal site to weaken junctional barrier
69
 and facilitate firm adhesion of leukocytes to 
ECs67. ECs form “migratory cups” by integrins, such as ICAM-1 and VCAM-170, which 
are re-located and concentrated on endothelial surface. Leukocytes adhesion and binding 
to ICAM-1 and VCAM-1 cause endothelial actin stress-fiber formation and increased 
permeability controlled by GTPases RhoA, Rho1 and Rap1
71
. This progression involves a 
number of cell adhesion molecules interactions. Importantly, Junctional adhesion 
molecule (JAM)-A, JAM-B, JAM-C and endothelial cell-selective adhesion molecule 
(ESAM) also promote trans-endothelial migration via homophilic and heterophilic 
interactions with integrins
67, 72, 73
. Leukocyte migration though endothelial basement 
membrane across gaps between adjacent pericytes and regions of low protein deposition 
within extracellular matrix is facilitated by integrins and proteases, such as matrix 
metalloproteinase (MMPs). 
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Figure 3: The leukocyte adhesion cascade (Ley K et al
66
). 
The traditional three steps of leukocyte adhesion are marked in bold. Rolling is mediated 
by selectins. Activation is mediated by chemokines. Arrest is mediated by integrins and 
immunoglobulin-superfamily members. Progress of leukocyte infiltration into vessel wall 
is defined in many steps: capture (or tethering), slow rolling, adhesion strengthening and 
spreading, intravascular crawling, and paracellular or transcellular transmigration. 
Leukocytes are directed by chemokines in flow or by immobilized chemokines gradients 
to migrate across the endothelium.  
Important molecules are described. ESAM, endothelial cell-selective adhesion molecule; 
ICAM1, intercellular adhesion molecule 1; JAM, junctional adhesion molecule; LFA1, 
lymphocyte function-associated antigen 1; MAC1, macrophage antigen 1; MADCAM1, 
mucosal vascular addressin cell-adhesion molecule 1; PSGL1, p-selectin glycoprotein 
ligand 1; PECAM1, platelet/endothelial-cell adhesion molecule 1; PI3K, 
phosphoinositide 3-kinase; VCAM1, vascular cell-adhesion molecule 1; VLA4, very late 
antigen 4
66
. 
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1.4 Platelets in vascular inflammation 
Platelets, also called “thrombocytes”, are first characterized in 19
th
 century as “small, 
curious beads or grains which accumulate with each other to irregular cluster” and 
nowadays are well known as anucleate cellular fragment shaped like a lens. The resting 
platelets at a diameter of 2-4µm are derived from megakaryocytes in bone marrow and 
show a lack of genomic DNA
74
, but contain megakaryocyte-derived mRNA for protein 
synthesis
75
. Platelet was initially only believed to play a pivotal role in physiological 
hemostasis and pathophysiological thrombosis, protect against bleeding and promote the 
stable blood clots formation via the coagulation cascade. Then it is considered important 
for thrombus formation upon plaque rupture. Now, these concepts have been expanded 
that platelets also assist and modulate inflammatory reactions, immune response, and 
atherosclerosis progression
76-78
.  
 
The vascular inflammation is a key process of atherosclerosis, accompanied and 
amplified by platelet activation and consequent interactions of platelets with ECs and 
leukocytes. Platelet interactions with leukocytes and ECs are regarded as important factor 
in the development and progression of atherosclerosis and neointimal formation. In the 
lesion sites, platelet-derived chemokines, with upregulated adhesion molecules, promote 
platelet adhesion and leukocyte recruitment, which eventually migrate into vessel wall. 
Under inflammatory conditions, platelets may already become activated in circulation or 
form platelet-leukocyte complexes with augmented capacities of adhesion and 
migration
78
. For example, it has been found that activated platelets can trigger and 
accelerate atherosclerosis in hyperlipidemic apoe
–/– 
mice, involving platelet surface 
receptors to promote recruitment of monocytes
9, 60
. The mechanisms underlying platelet-
leukocyte interactions involve a number of important molecules, for instance, selectins 
with their ligands, and integrins binding to Ig-like cell adhesion molecules as well as to 
glycoprotein, importantly von willebrand factor (vWF), which can be found in plasma, 
extracellular matrix and activated endothelial cells. So the platelet can been considered as 
pivotal mediator in vascular inflammation. 
 
Introduction 
12 
 
Various studies show that platelets are initiators and propagators of atherosclerosis
60
, by 
release of cytokines and interactions with other cells, promoting recruitment of various 
inflammatory cells to the vessel wall and fostering processes such as atherosclerosis, 
neointimal formation and thrombosis, but also vessel repair and regeneration after 
vascular injury. For example, Henn and colleagues found that platelets expressed CD154 
within seconds after activation in vitro and in the process of thrombus formation in vivo. 
Interestingly, CD154 on platelets was found to stimulate ECs to secrete chemokines and 
express adhesion molecules, thereby generating signals for the recruitment and 
extravasation of leukocytes at atherosclerotic predilection sites. Thus, platelet can directly 
initiate an inflammatory immune response. In addition, IL-1β secreted by platelets can 
induce expression of CCL2 and ICAM-1 in ECs
79, 80
, indicating the alterations of 
chemotactic and adhesive properties of ECs due to platelet activation. In carotid arteries 
of apoe–/– mice, platelets were shown to interact with endothelium of atherosclerosis-
prone sites in GPIbα- and integrin αIIbβ3-dependent manner. These interactions appeared 
to precede expression of adhesion molecules and subsequent extravasation of monocytes, 
ultimately leading to plaque development
9
. Transient platelet-endothelium interactions 
are sufficient for the deposition of the chemokines CCL5 and CXCL4
81
, which further 
propagates plaque development60, 82.  Under transient interactions mediated by P-selectin, 
adherent platelets form an adhesive substrate for inflammatory cells, such as neutrophils, 
and subsequently secrete platelet-activating factor (PAF) to stimulate neutrophils 
adhesion and spreading on endothelium
83
. P-selectin on platelets also plays an important 
role in cell interactions and promotes the fatty streaks formation at atherosclerotic early 
stage84. Activated platelets activate endothelium, inhibit endothelial regeneration and 
promote foam cell development
85
, playing an important role in the vascular inflammation. 
1.5 Platelet interaction with endothelial cells and leukocytes 
The transient and stable interactions of platelets with ECs depend on different platelet 
receptors, which can result in the development and progression of atherosclerosis
78
. 
However, health, non-activated endothelium can prevents platelets adhesion by its 
antithrombotic properties, involving releasing platelet activation-inhibiting substances 
Introduction 
13 
 
such as NO, prostacyclin and cyclooxygenase-2
86
. After endothelial cell activation, it can 
change phenotype from anti-thrombotic properties to pro-thrombotic properties, 
characterized by releasing of platelet-binding and stimulating agents, such as ADP, vWF, 
tissue factor (TF) and adhesion molecules
87
. Firstly, transient rolling is mediated by 
platelets GPIb with P-selectin, which is a cell adhesion molecule expressed by platelets, 
ECs and macrophages
88
. P-selectin is stored in granules called Weibel-Palade bodies of 
un-activated ECs or in α-granules of un-activated platelets, which can be rapidly 
transported to cell surface after activation, allowing leukocytes and platelets interaction 
quickly with ECs during inflammation. Another primary ligand of P-selectin is P-selectin 
glycoprotein ligand-1(PSGL-1) expressed on almost all leukocytes, platelets and 
endothelial cells
89
. Beside the traditional way of platelet rolling mediated by P-selectin-
PSGL-1, transmembrane GP EMMPRIN (CD147) on activated platelets with endothelial 
counter-receptors GPVI90 and E-selectin91, can also mediate platelets rolling. 
Subsequently, stable adhesion of platelets to inflamed endothelium mediated by 
additional molecules, such as GPIb-IX-V with vWF and GPVI with collagen interactions 
respectively, results in platelet activation, characterized by integrins αIIbβ3 (GPIIbIIIa, 
fibrinogen receptor) and α2β1 (collagen receptor) activation
92
. The activated integrins are 
essential and required for stable adhesion of platelets to extracellular matrix and ECs.  In 
addition, the integrins on platelets can directly bind to collagen, vWF and endothelial 
adhesion molecules, or indirectly bind via additional bridging molecules, such as 
fibrinogen, fibronectin or vWF, to endothelial activated ICAM-1, αvβ3 integrin, and 
GPIb, respectively
93, 94
. Meanwhile, novel mechanisms have shown that membrane-
bound chemokine CX3CL1 expressed on inflamed endothelial cells can stabilize platelet-
endothelium interactions
95
. Except heterophilic interactions, platelets can also interact 
with ECs by molecular homophilic interactions, such as JAM-A-JAM-A interaction
96
.  
 
Platelet adhesion induces endothelium pro-inflammatory phenotype, marked by platelet 
spreading and activation, upregulated expression of adhesion molecules, such as P-
selectin, CD40L, TNFSF14 and secretion of pro-inflammatory substances, such as IL-1β 
and CXCL4
78, 97
. IL-1β can in turn induce ECs to secrete CCL2, GM-CSF, IL-6 and to 
upregulate expression of ICAM-1 and αvβ3 integrin, involving activated NF-κB 
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pathway
79, 98
. Additionally, CD40L (CD154), which is stored in significant amounts in 
platelets and released within seconds by αIIbβ3 activation, can bind to endothelial CD40, 
including increased secretion of endothelial CXCL8 and CCL2, expression of adhesion 
molecules, urokinase type plasminogen activator (uPAR) and matrix metalloproteinase 
(MMP)-2 and -9,  and production of reactive oxygen species (ROS)
99-101
.   
 
Except platelet-endothelium interaction, activated platelets also show robust interactions 
with leukocytes, characterized by increase of circulating platelet-leukocyte complexes. In 
particular, increased platelet-monocyte complexes (PMCs) have been observed in clinical 
conditions, such as peripheral vascular disease, hypertension
102
, acute or stable coronary 
syndrome
103-105
, stroke
106
, or diabetes
107
. Conversely, high dietary intake of omega-3 fatty 
acids reduces activated platelets and PMC levels, associated with reduction of 
cardiovascular events108. The presence of PMCs is not only a sensitive marker for platelet 
activation and cardiovascular diseases but is also regarded more and more as a 
cardiovascular risk factor
106, 109
.  
 
Platelets binding to monocytes shows more and initial faster, compared with neutrophils, 
so the researches focusing on PMCs are more intensive. P-selectin expressed on surface 
of activated platelets mediates the binding to monocytes via PSGL-1, which determinate 
the extent of PMCs formation
110
. The binding of platelets to monocytes via P-selection-
PSGL-1 induces L-selectin shedding from the monocyte surface and upregulates 
expression and activity of integrins α4β1 and αMβ2 (Mac-1)
111
, which in turn stabilizes 
the adhesion via MAC-1 to the GPIbα. Similarly, involvement of CD40-CD40L increases 
the expression of β1- and β2-integrin for platelet-monocyte adhesion and recruitment into 
the injured vessel wall
112
. In addition, activated platelets via P-selection-PSGL-1 or 
GPIbα-MAC-1 interactions can induce an inflammatory cascade in monocytes, such as 
upregulated expression and secretion of chemokines via NF-κB activity
113-115
. 
Furthermore, the chemokines from activated platelets can be deposited on monocytes in 
PMCs, which induce monocytes activation, adhesion molecules expression and cytokines 
secretion, such as TNF-α and CXCL8
116, 117
. Importantly, PMCs have been upregulated 
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integrin expression and activity compared with platelet-free monocytes and increased 
monocyte adhesion and transmigration capacity
118
.  
1.6 Platelet chemokines 
Chemokines are a family of small chemotactic cytokines, with a molecular weight 
ranging from 8-10 kDa, containing 60-100 amino acids. There are approximately 50 
different chemokines, which are classified into four subclasses, CXC-, CC-, C- and 
CX3C-chemokines, based on the relative position of the first consensus cysteins on N-
terminal part of proteins. Chemokines regulate cell functions, including immune survival, 
development, hematopoiesis, wound healing, inflammation, viral infections or 
metastases119. Especially, the trafficking and extravasation of leukocytes are governed by 
chemokines during immune surveillance and inflammation.  
 
Chemokine receptors are large proteins binding different chemokines and chemokines 
themselves are able to bind several different receptors. All chemokine receptors are 
specific cell surface G-protein-coupled receptors (GPCRs), consisting of about 350 
amino acid residues and sharing common structural features: an extracellular amino-
terminus (N-terminus), a polypeptide which loops across the membrane seven times to 
form three intracellular and three extracellular loops, a disulfide bond linking cysteine 
residue in the first and second extracellular loops and last an intracellular carboxyl-
terminus (C-terminus)120. Moreover, most chemokines also display a high affinity to a 
class of polysaccharide called glycosaminoglycans (GAGs). GAGs are present on all cell 
surfaces and in intracellular matrix, which can covalently attach to core proteins121. This 
bound facilitates chemokines immobilization and gradients formation
122
. When 
chemokine binds to its receptor, conformational changes are induced and result in 
receptor activation and signal transduction.  
 
Platelet-derived chemokines are synthesized in megakaryocytic precursor cells and stored 
in α-granules of mature platelets, regulating inflammatory progress, atherosclerosis, 
neointimal formation and angiogenesis. PF4 (CXCL4) was the first chemokine 
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discovered in releasates from platelets
123
, involving in proliferation, apoptosis and 
differentiation of immune cells
124
. CXCL4 can bind to a 200 kDa chondroitin sulfate 
proteoglycan on the surface of human neutrophils,125 and has also been shown to bind to 
CXCR3B, a splice variant of CXCR3, but not to CXCR3A, which is a receptor expressed 
on ECs and T cells, not on monocytes or neutrophils
126
. However, the chemotactic 
activity of human T cells towards to CXCL4 is mediated by both CXCR3 variants in a 
PTX-sensitive manner
127
. Human neutrophil adhesion in response to CXCL4 is blocked 
after treatment with a Src kinase inhibitor or other inhibitors for Syk, RAS and JNK, 
whereas PF-4-mediated exocytosis requires the additional activation of p38 MAP kinase 
and phosphatidylinositol 3-kinase
128
. These findings suggest that CXCL4 can trigger 
more than one signaling pathway. 
 
In atherosclerosis, CXCL4 was found in early and late lesions of carotid artery, 
correlating with clinical outcome
129
. CXCL4 deficiency in apoe
–/– 
mice or transplantation 
of CXCL4 deficient bone marrow into apoe
–/– 
mice decreased atherosclerotic lesions 
formation with reduced macrophage infiltration
82
. However, since highly purified 
CXCL4 lacks chemotactic activity for neutrophils, monocytes and T cells
130
, the 
mechanism of CXCL4 influence on atherosclerosis needs more investigation. 
Additionally, CXCL4 have been described to induce cells differentiation, such as 
monocyte differentiation to macrophages
131
 or specialized antigen-presenting cells
132
, 
apart from its potential role in conjunction with CCL5 in monocyte recruitment to vessel 
wall
133
. So CXCL4 may increase atherogenesis by promoting differentiation of 
monocytes into macrophages and foam cells.  Furthermore, CXCL4 induces higher 
phagocytic capacity as compared to GM-CSF-induced macrophages
134
. Some 
experiments found that CXCL4 can bind to the oxLDL particles, resulting in increased 
uptake by macrophages and foam cell formation
135
, which would be expected to promote 
foam cell formation in atherosclerotic lesion. Additionally, CXCL4 exerts effects on 
inhibition of cell proliferation and angiogenesis in ECs136. This inhibition was also shown 
that CXCL4 inhibits proliferation and cytokine release from activate T cells in vitro
137
. 
 
Introduction 
17 
 
CCL5 (RANTES) is a chemokine with a molecular mass of 7.8 kDa and secreted by 
various cell types such as ECs, SMCs, macrophages, activated T cells and platelets. 
Binding to CCR1, CCR3, CCR4 and CCR5 receptors and inducing transient calcium 
influx, CCL5 plays an important role in monocyte and T lymphocyte recruitment in 
inflammation and atherosclerosis
138, 139
.  The signal transduction induced by CCL5 in T 
cells results in focal adhesion and subsequent cell activation via a molecular complex 
containing focal adhesion kinase, the tyrosine kinase zeta-associated protein (ZAP) 70 
and paxillin
140
. Additionally, after exposure to CCL5, the intracellular intergrin-domain 
of monocytes and lymphocytes are phosphorylated for the adhesion
141
. In neointimal 
lesions after wire-induced carotid injury of apoe
–/– 
mice, CCL5 has been primarily 
detected on ECs and was possibly deposited from activated platelets and neointimal 
SMCs. Most notably, CCR5 has been shown as a potential therapeutic target of anti-
inflammation, for example, CCR5 antagonist maraviroc (UK-427857) is admitted as an 
HIV-inhibitor and was shown to reduce atherosclerosis in the murine system without 
affecting lipid levels
142
. 
1.7 Junctional adhesion molecules 
 Junctional adhesion molecules in inflammation 1.7.1
Junctional Adhesion Molecules (JAMs) are transmembrane proteins belonged to 
immunoglobulin superfamily. JAM-A (CD321, JAM-1 or F11 receptor) initially called 
F11 receptor was recognized as a receptor for platelet activating antibody F11
143
. Other 
family members are JAM-B, JAM-C, JAM-4, ESAM and JAM-like (JAM-L) proteins. 
They are expressed in tight junctions of endothelial and epithelial cells and also in 
circulating cells that do not form junctions, such as leukocytes and platelets. These 
proteins control vascular permeability by regulating barrier function of tight junctions 
and facilitate leukocyte transmigration across endothelium through homophilic, 
heterophilic and lateral interactions. Their expression, location and function are regulated 
by inflammatory cytokines and growth factors, and they also translate extracellular 
adhesive events into functional responses. Antibody-blocking studies and studies using 
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genetically modified mice have implicated JAMs functions in regulation of leukocyte 
recruitment to sites of inflammation and ischemia-reperfusion injury, and in vascular 
remodeling, such as growth-factor-mediated angiogenesis, atherosclerosis and neointimal 
formation. JAMs may regulate leukocyte recruitment by redistributing to luminal surface 
under inflammatory conditions and may promote leukocyte movement through 
intercellular junctions. However, the signaling cascades through JAMs remain 
incompletely clear. Furthermore, their functions are considerably various in different 
tissues under cell-specific and context-dependent conditions among different members of 
the JAMs (Figure 4)
73
. 
 
JAMs have an extracellular domain with two immunoglobulin-like domains (membrane-
distal V-type and membrane-proximal C2-type), a single transmembrane segment and a 
short cytoplasmic tail with a phosphorylation site for protein kinase C (PKC) and a PDZ-
domain-binding motif linking to tight junction-associated scaffold proteins such as zonula 
occludens 1(ZO-1), afadin 6 (AF-6), ASIP/Par3, cingulin.  
 
Increasing evidence points a role of JAMs in vascular inflammation. An up-regulation of 
JAMs expression on atherosclerotic endothelium and early lesions has indicated a role of 
JAMs in plaque formation, such as increased expression of JAM-A and JAM-C at the 
protein and transcript level induced by oxidized lipoproteins (rather than cytokines) under 
hyperlipidaemic conditions in apoe-deficient mice
144, 145
. JAM-C on atherosclerotic 
endothelium can mediate MAC1-dependent transmigration of leukocytes
98
, and a 
function of JAM-A in early atherogenesis was inferred by soluble JAM-A inhibiting 
leukocytes accumulation
138
. Furthermore, up-regulation of JAM-A expression in unstable 
human plaques concomitant with increased macrophage infiltration further implies its 
role at later stages of lesion development and progression
146, 147
, indicating its 
involvement in the rupture of atherosclerotic plaque. 
 
Apart from directly contributing to leukocytes recruitment, JAMs expressed on platelets 
have additional mechanisms that regulate atherosclerosis progression. Platelet JAM-C 
may promote atherothrombosis through the engagement of MAC-1 to mediate leukocyte-
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platelet interactions or to promote the recruitment of such complexes
148
. JAM-A on the 
surface of platelet was found to participate in platelet adhesion to endothelium under 
inflammatory conditions96. Transient interactions of platelets with early atherosclerotic 
endothelium can lead to endothelial deposition of platelet chemokines, such as CCL5, 
which trigger other platelet-dependent mechanisms and leukocytes recruitment to 
aggravate atherosclerosis
60, 81
. Moreover, PMPs shed from activated platelets mediate 
CCL5 deposition by transient tethers on activated endothelium, also involving JAM-A 
signals149. Indeed, CCL5 deposition by JAM-A deficient platelets on endothelium is 
impaired
39
. Thus, platelets use JAM-A engagement during interactions with ECs. In 
addition, JAM-A has also been identified on SMCs in atherosclerotic lesions, but its 
contribution remains unclear
145
. Most notably, how JAM-A regulates platelet activity in 
atherosclerosis attracts us to investigate. 
 
JAM-B expression is restricted to ECs and localizes mainly in the junctions of high 
endothelial venules and of heart, and not detected in leukocytes. Additionally, JAM-B is 
more expressed in chronic inflammatory tissues in asthma, bronchitis, interstitial 
nephritis, autoimmune hepatitis and alcoholic cirrhosis
150
. JAM-B heterophilically 
interacts with integrin VLA-4 and JAM-C, but JAM-B–VLA-4 interaction depends on 
JAM-C. For example, T cells lacking functional JAM-C did not show any JAM-B–VLA-
4 interaction
151, 152
. Furthermore, JAM-B and -C are involved in leukocyte extravasation 
to sites of inflammation, determined by the evidence that JAM-B and -C play a role in 
leukocyte extravasation to the inflammation of skin. JAM-B and -C have overlapping, but 
distinct functions in regulating leukocyte transmigration. JAM-B may predominately 
govern neutrophil transmigration, whereas JAM-C may govern edema formation, 
however, further studies are required to investigate molecular mechanisms of JAM-B and 
-C mediated leukocyte migration in vascular inflammation
153
. 
 
JAM-C is expressed in ECs and lymphocytes including monocytes, natural killer cells, 
dendritic cells, B cells and T cells. Through hemophilic and heterophilic interactions with 
JAM-B and MAC-1, JAM-C plays an important role in vascular inflammation through 
regulating leukocyte transmigration. Woodfin et al. found that JAM-C rather regulates 
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polarized leukocyte transmigration in a sense that it blocks leukocyte reverse endothelial 
transmigration
154
. Furthermore, increased expression of JAM-C was found in 
atherosclerotic lesions of apoe–/– mice, together with a re-localization away from 
endothelial cell junctions to the apical site
144
. Blocking JAM-C decreased neointimal 
hyperplasia after wire injury of carotid arteries
155
. 
            
 
Figure 4: Structural features, homophilic adhesion and extracellular ligands of 
JAMs. (Weber et al.
73
) 
A. JAMs structure contains two immunoglobulin-like domains in extracellular portion, a 
single transmembrane segment and a short cytoplasmic tail with a PDZ domain-binding 
motif (Phe-Leu-Val). The short linker sequence (Val-Leu-Val) connects two 
immunoglobulin domains to impose a bent conformation. The dimerization motif (Arg-
Val/Leu/Ile-Glu) in membrane-distal domain is essential for homodimer formation. B. 
Homophilic interactions of JAM-A in cis (via dimerization motif in the membrane-distal 
immunoglobulin domain) in a shape of an inverted ‘U’. These cis-homodimers bind in 
trans to JAM-A homodimers of an adjacent cell surface at intercellular junctions. C. 1) 
Homophilic and heterophilic interactions of JAM-A, JAM-B and JAM-C regulate 
endothelial permeability. 2) Homophilic interaction of JAM-A mediates platelet adhesion 
to endothelium. Heterophilic interactions of JAM-C–integrins support platelet adhesion 
to leukocytes. 3) Crosstalk of JAMs and integrins supports leukocytes binding to 
endothelium, such as the interactions of integrin lymphocyte function-associated antigen 
1 (LFA1) with JAM-A, very late antigen 4 (VLA4) with JAM-B, and JAM-C with 
MAC1. 
A B C 
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 Junctional Adhesion Molecule A  1.7.2
Murine and human JAM-A was first characterized in 1998 and 1999 respectively156, 157.  
JAM-A sharing about 70% amino acid identity is highly conserved among mammals
156
.  
In extracellular domain, two Ig-like domains are connected by a linker of 3 amino (val-
leu-val) to form a bent 125
0
 conformation, which is stabilized by hydrogen bonding. The 
membrane-distal V-type domain contains a dimerization motif, major for homodimer 
formation.  
 
JAM-A is mostly abundant in tight junctions of endothelial and epithelial cells in various 
organs including liver, kidney, pancreas, heart, brain, lymph nodes, intestine, lung, 
placenta and vascular tissue
156
. Furthermore it is expressed in lymphoid and myeloid 
origin157. Inflammatory cytokines regulate JAM-A junctional, such as TNF-α and IFN-γ 
treatment of endothelial cells leading JAM-A re-localization from intercellular junctions 
to luminal surface, although expression levels remains unchanged69, 156. In vivo, JAM-A 
expression is upregulated on atherosclerotic endothelium and in unstable atherosclerotic 
plaques
146, 158
. Similarly, JAM-A expression is increased on hepatic venular endothelium 
after ischemia-reperfusion injury
159
. JAM-A re-localization might be involved in 
atherosclerosis
40
. In another study on brain endothelial cells, CCL2 induced JAM-A re-
distribution from inter-endothelial cell area to apical surface, associated with 
internalization via micropinocytosis during para-cellular route opening. Internalization of 
JAM-A within a short time period (<10 min) and redistribution of most internalized 
JAM-A to the brain endothelial cell apical membrane involve Rho family kinase as well 
as actin reorganization
160
.  
 
JAM-A displays different patterns of homo- and heterophilic adhesions. The interaction 
and function of JAM-A with its partners play an important role in regulation of 
endothelial permeability and are therefore a pivotal component of inflammatory reactions. 
An over-expression of JAM-A increases endothelium barrier function by interaction in a 
homophilic manner with neighboring molecules (in cis) and in dimeric state with other 
dimers from adjacent cells (in trans), forming a tight, zipper-like structure. It also 
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interacts with β2 integrin leukocyte function-associated antigen 1 (LFA-1; integrin αLβ2; 
CD11a; CD18), which is associated with trans-endothelial cell migration and leukocytes 
recruitment, such as monocytes and neutrophils (figure 4)161. A typical feature of JAM-A 
in endothelial-leukocyte interactions is a contribution to specific ring-like structure that 
forms on ECs surrounding a transmigrating leukocyte. Another evidence showed that 
JAM-A, together with CD99 and CD31, forms a transient ring structure facilitating 
leukocyte transmigration
73
. The ring-like structures play an active role in organizing 
leukocytes transmigration.  
 
JAM-A also play a role in angiogenesis. Naik and his colleagues found that basic 
fibroblast growth factor (bFGF)-induced angiogenesis depends on JAM-A/αvβ3 integrin 
complex through JAM-A signaling
162, 163
.  In addition, JAM-A on CD34
+
 stem cells 
mediates adhesion to the vessel wall after injury and differentiation into endothelial 
progenitor cells to facilitate re-endothelialization
164
. JAM-A is crucial for correct 
endothelial cell motility, directional movement and focal contact formation and CD34
+
 
stem cell differentiation, and thereby might be involved in angiogenesis in endothelial 
recovery after vascular injury.  
 
Endothelial JAM-A is expressed in tight junction and re-localized to the apical surface 
under inflammatory conditions. Using a blocking monoclonal antibody against JAM-A 
on cultured endothelial cells inhibit monocyte transmigration
156
. Furthermore, treatment 
with a monoclonal antibody against JAM-A significantly inhibit leukocyte accumulation 
in cerebrospinal fluid and infiltration in brain parenchyma165. In atherosclerosis, 
endothelial JAM-A facilitates plaque formation. In early lesions of carotid arteries from 
apoe-deficient mice, endothelial JAM-A mRNA and protein expression increased
145
, 
similar in human atherosclerotic plaque
158
.  The increase of endothleial JAM-A in human 
atherosclerotic plaque also was validate by microarray technique
146
, which might 
facilitate leukocytes infiltration and increase plaque volume. Recently, we demonstrated 
that JAM-A has a cell type-specific impact on atherosclerotic plaque formation. Whereas 
endothelial JAM-A promoted plaque formation by enhanced luminal availability under 
pro-atherosclerotic conditions, thus guiding monocytes to sites for plaque development. 
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The expression and luminal enrichment of JAM-A was exacerbated by disturbed flow 
conditions, as encountered at predilection sites, conversely, laminar shear flow induced 
microRNA-145 to repress JAM-A expression, indicating the contribution of limiting the 
susceptibility to atherosclerosis
40
. This gave a novel explanation of the higher 
susceptibility to atherosclerosis in regions with disturbed shear flow. Targeting 
endothelial JAM-A may serve as a feasible option to protect against vascular 
inflammation.  
JAM-A on circulating leukocytes, including monocytes, lymphocytes, dendritic cells and 
neutrophils, mediates cells migration together with their integrins, but it shows cell-
specific impact. On monocytes, not much is known about the specific roles of JAM-A. 
The only evidence is reduced monocyte adhesion to atherosclerotic endothelium of 
carotid artery perfused with monocytes pretreatment of soluble JAM-A.Fc in a VLA-4 
independent manner
145
. On T cells, pretreatment of JAM-A antibody or soluble JAM-
A.Fc in vitro assays reduced T cell arrest under flow conditions and trans-endothelial 
chemotaxis towards SDF-1
145
. However, JAM-A on polymorphonuclear cells reduced 
diapedesis with impaired de-adhesion and polarized motility in peritonitis and ischemia-
reperfusion injury
166
. Recently, our group found that JAM-A deficient monocytes indeed 
displayed defects in de-adhesion and complete trans-endothelial migration, likely a result 
of persistently increased activity of β2 integrins, because monocytes were entrapped 
between the endothelial cell layer and the basement membrane and may thereby cause 
vascular damage. Leukocyte JAM-A might limit lesion formation by enabling 
physiological de-adhesion and migration of mononuclear cells
40
.  
 
On dendritic cells, JAM-A deficiency caused an increased random motility and 
transmigration across lymphatic ECs but not microvascular ECs. In vivo, JAM-A
–/–  
mice 
showed enhanced DC migration to lymph nodes, whereas endothelial JAM-A deficiency 
did not alter dendritic cell transmigration
167
,  indicating a specific role of JAM-A in 
dendritic cell migration. 
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On neutrophils, JAM-A deficiency leads to defective uropod retraction and trans-
endothelial migration in inflammatory models of peritonitis and heart 
ischemia/reperfusion as well as in adhesion and tans-migration assays166. Additionally, 
JAM-A
–/– 
neutrophils adhered more efficiently to ECs and basement membrane proteins 
and their polarized movement was strongly reduced. Thus, JAM-A control neutrophil 
diapedesis through vessel wall. On activated neutrophils, JAM-A concentrated in a 
polarized fashion at the leading edge and uropod, while a significant amount of JAM-A is 
internalized and co-localized with integrin β1. JAM-A–/– neutrophils are unable to 
internalize integrin β1 upon chemotactic stimuli and this leads impaired uropod retraction 
and polarized cell motility. These phenotypes indicate that JAM-A is required for the 
internalization and recycling of integrins during neutrophil migration and might explain 
that the directional migration of JAM-A
–/– 
neutrophils is impaired
168
. The small GTPase 
Rap-1 plays a role in integrin internalization and it´s activity is reduced in JAM-A–/– 
neutrophils
169
. These evidences indicate that JAM-A on neutrophils controls the regulated 
migration cascade combined with integrins. 
 
Notably, the F11 receptor was found on the surface of human platelets and is a member 
of immunoglobulin superfamily170. A monoclonal antibody MabF11 against this 
membrane protein could cause platelet activation, such as platelet aggregation, granule 
secretion and phosphorylation of intracellular proteins
143
. In another study, this antibody 
activated platelets through cross-linking of JAM-A with FcγRII receptor on the 
membrane, triggering actin filament assembly with conversion of discoidal platelet to 
activated shapes and leading to platelet aggregation. The actin filament assembly is 
dependent on phosphoinositide-3 kinase activation
171
. Additionally, JAM-A was found to 
be phosphorylated in thrombin and collagen activated platelets, thus initially hinting 
towards a physiological role
172
, despite the adhesion function. Thus, intensive 
investigation about JAM-A on platelets has occured in past years. 
 
Human JAM-A cloned into Chinese hamster ovary (CHO) cells revealed that JAM-A 
accumulated on the cell surface and enhanced localization between two adjacent cells
170
. 
Furthermore, the intracellular tail of JAM-A was found to be co-localized with cortical f-
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actin, but not with cell-spanning stress fibers. Interestingly, less platelet adhered to 
immobilized JAM-A
–/– 
CHO cells compared with JAM-A expressing CHO cells, 
providing initial for cell–cell binding mediated by JAM-A hemophilic interactions170. 
Additionally, Babinska and colleagues found that platelets specifically adhered to a 
matrix made of immobilized JAM-A molecules. They also reported that platelets 
adhesion to cytokine-(TNF-α, INF-γ) activated HUVEC monolayers, is mainly mediated 
by homophilic interactions between JAM-A of platelets and EC
96
. Thus, JAM-A through 
homophilic interactions mediates platelet-platelet and platelet-endothelial cells adhesion. 
 
Mounting evidence suggests that JAM-A regulates platelet activation, dependent on 
integrin αIIbβ3. Interestingly, JAM-A-deficiency was shown to cause platelet 
hyperreactivity. On resting platelets, the conformation of integrin αIIbβ3 under low-
affinity is converted to a high affinity state after platelet activation, known as inside-out 
signaling
173
. Ligand binding to the activated integrin triggers cascade signaling events, 
named outside-in signaling
174
. Timely and rapid activation of integrin is pivotal for 
hemostasis, but unwanted activation can result in thrombosis
175
. However, the effects of 
unwanted or accidental activation of integrin in atherosclerosis, is unclear.  
 
Integrin outside-in signaling for platelet activity begins to be characterized. The signal 
molecule c-Src binding with integrin, a member of the Src family kinase (SFKs), plays an 
important role in outside-in signaling
176
. In resting platelets, Src is kept in inactive state 
through two intramolecular interactions, including the binding of the Src homology 3 
(SH3) domain to a polyproline type II helix and the other binding through its Src 
homology 2 (SH2) domain to a phosphotyrosine residue (Y
529
) in the C-terminal 
regulatory domain
177
.  Maintaining SFKs in an inactive state requires phosphorylation of 
the C-terminal inhibitory Y
529 
residue by cytoplasmic kinases Csk (C-terminal Src kinase) 
or Csk homologous kinase. SFKs dephosphorylation can trigger integrin outside-in 
signaling. However, Csk should be recruited nearly to sites of Src to suppress Src activity. 
Thus, the molecule, which recruits Csk to Src, becomes very important. It has been found 
that JAM-A binding Csk forms complex with integrin, so JAM-A as the linker between 
Csk and Src to form a complex (Csk-JAM-A- integrin αIIbβ3-Src) maintains Src Y
529
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phosphorylation in an inactive state
178
. After platelet activation, JAM-A detaches with 
Csk and is rapidly phosphorylated by PKC
179
, followed by the complex disruption. 
Losing CSK, Scr Y529 is dephosphorylated and triggers downstream signaling. However, 
the signaling pathway still need more research, such as Scr activity after detaching from 
the complex.  
 
Like other cell adhesion molecules (CAMs) as negative regulator for platelet activation
180
, 
JAM-A as a negative regulator controls platelet activity, such as protection from 
thrombosis
181
. JAM-A negatively regulates platelet function in vivo, which was certified 
by JAM-A–deficient
 
mice undergoing a pro-thrombotic phenotype. Additionally, 
transplantation of JAM-A–deficient
 
platelets into wild-type background also displays a 
pro-thrombotic phenotype. In these mice, JAM-A–deficient
 
platelets hyper-aggregate in 
response to a low dose of physiologic agonists, are named hyperreactivity. This 
hyperreactivity of JAM-A–deficient
 
 platelets is not due to augment of inside-out 
signaling, such as granular secretion, Thromboxane A2 (TxA2) generation and integrin 
activity, but due to the enhanced outside-in signaling as increased αIIbβ3 
phosphorylation
181, 182
. 
 
As more evidencs proposed that platelets are initiators and propagators of 
atherosclerosis
60
 and JAM-A might regulate platelet function during thrombosis and 
atherosclerosis
96, 171, 183
. Now we believed that platelet JAM-A displays two distinct 
functions. First, JAM-A mediates integrin αIIbβ3 dependent platelet activation. Second, 
JAM-A mediates platelet adhesion independent of integrins or fibrinogen receptors via 
homophilic JAM-A interactions with other cell types, thus playing a role in physiological 
processes important for platelet aggregation. But little is known the detailed functions 
about JAM-A regulating platelet in atherosclerosis. 
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2 The aims of this study 
Background: Platelets have an essential role in hemostasis and also act as immune cells 
to spark vascular inflammation. As the first circulating cells adhering to atherosclerotic 
predilection sites and to injured vessel wall, platelets promote leukocyte migration into 
vessel wall, which is the main driving force of vascular inflammation and remodeling. 
Platelets can bridge leukocyte adhesion to endothelium and also secrete cytokines for 
leukocytes recruitment. Thus, platelets are implicated as initiator and propagator of 
vascular remodeling. Although loss of platelet function reduces atherosclerotic plaque 
formation in hyperlipidemic mice60, 77, in fact, very few studies can address whether 
platelet hyperreactivity augments vascular inflammation and remodeling or not. 
 
JAM-A as an adhesion molecule regulate endothelial permeability, platelet activity and 
leukocytes migration. But it shows cell-specific roles in different cell types. Somatic 
deficiency of JAM-A led to decreased neointimal formation, but no effect on plaque 
formation. JAM-A on endothelial cells and leukocytes appears to have opposite roles for 
plaque formation
40
. Thus, it is worthwhile to investigate functions of platelet JAM-A in 
vascular remodeling. Furthermore, JAM-A inhibits platelet activity through outside-in 
signaling of integrin αIIbβ3. Deletion of JAM-A in platelets caused hyperreactivity181, 182, 
but whether a lower activation threshold of platelets leads to platelet-mediated increase of 
vascular inflammation in vivo needs to be investigated. In addition, the molecular basis 
for the regulation of integrin signaling by JAM-A is not yet fully characterized. 
 
The aims of this study were: 
 
1. To find out whether trJAM-A–deficiency affects atherosclerotic development and 
neointimal formation after vascular injury in hyperlipidemic mice. 
2. To determine how trJAM-A–deficiency causes platelet hyperreactivity.  
3. To investigate the interactions among JAM-A-deficient platelets, leukocytes and 
inflammatory endothelium in the context of vascular inflammation. 
4. To find out how platelet hypereactivity affects chemokine secretion. 
5. To elaborate the signaling cascade of JAM-A regulating platelet activity through 
integrin αIIbβ3. 
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3 Materials and Methods 
The general chemicals were purchased from Fluka (Buchs, Switzerland), Sigma 
(Deisenhofen, Germany) or Roth (Karlsruhe, Germany) in analytical grade quality, unless 
indicated otherwise. All reagents, buffers and solution were prepared with double 
distilled water (Heraeus Destamat, Heraeus, Germany) or Millipore water (Milli-Q Plus 
ultrapure purification, Millipore, MA). All protocols were adapted from standard 
protocols unless otherwise described. 
3.1 Materials 
 Instruments 3.1.1
Equipment Manufacturer 
Balance  Analytical Plus, Ohaus, Pine Brook, USA 
Centrifuge Centrifuge5415 R, Eppendof 
Heraeus®Multifuge®3S-R, Thermo Scientific 
Digital camera Leica DFC365 FX, Leica Microsystems, Germany 
Embedding machine Leica EG1160, Leica biosystems, Germany 
Flow cytometers FACS Canto II, BD Biosciences, San Jose, CA, 
USA 
Hematology analyzer ScilVet ABC, scil Animal Care 
Hematology analyzer ScilVet ABC, scil Animal Care 
Microscope Leica DM RBE, Leica Microsystems, Germany 
Multiplate® platelet analyzer Roche Diagnostics, Mannheim, Germany 
Microplate reader GENios,Tecan, Männedorf, Switzerland 
PH-meter InoLab level 1,WTW, Weilheim, Germany 
Stereomicroscope Leica S6, Leica Microsystems, Germany          
Stemi:2000-c,  Zeiss 
Tissue Processor(dehydration) Leica ASP200 S, Leica biosystems, Germany 
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 Reagents and materials 3.1.2
General Reagents and materials Catalog number Manufacturer 
4% buffered formaldehyde P087.3 Carl Roth 
4'.6-diamidino-2-phenylindole(DAPI) H-1500 Vector Labs 
Adenosine diphosphate (ADP) 50704 Biopool 
Antigen retrieval solution S1699 Dako 
Antagonist(antiamzolhydrochlorid) 400936 Cp-pharma 
Bovine serum albumin (BSA) 11922 SERVA 
CCL5/RANTES ELISA Kit DY478 R&D Systems 
Cholesterol-CHOD-PAP kit 12016630122 Cobas 
Citrate-coated tubes 352052 BD Falcon 
CXCL4/CXCL4 ELISA Kit DY595 R&D Systems 
DC protein assay kit 500-0111 Bio-Rad 
Dimethyl sulfoxide (DMSO) A994.1 Roth 
EDTA-coated tubes 41.1504.005 Sarstedt 
Elastica van Gieson (EVG) staining kit 12739 Morphisto 
Ethanol 9065.3 Roth 
FACS tubes 352052 BD Falcon 
Fixation/permeabilization solution kit 554714 BD Bioscience 
Fibrinogen CT15 Oxford Biomedical 
Research 
Goat serum X0907 Dako 
Hank's Balanced Salt Solution (HBSS) 14065-049 Life Technologies 
Isopropanol 109634 Merck millipore 
KB SRC4 (Src inhibitor) 4660 Tocris 
Ketamine 618926 pfizer 
2x Laemmli Sample Buffer 161-0737 Bio-Rad 
Medetomidine 45081 Pfizer 
Oil Red O O0625-100G Sigma Aldrich 
PP2 (Src inhibitor) 529573 Merck millipore 
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Protein G-coupled magnetic beads 10003D Life Technologies 
PTP inhibitor IV 540211-10MG Merck millipore 
PTP1B inhibitor 539741 Merck millipore 
SHP1/2 PTPase inhibitor (NSC-87877) 565851 Merck millipore 
SU6656 (Src inhibitor) S9692 Merck millipore 
Surgical suture 7/0 IO 051391 Serag Wiessner 
Suture clips BN507R Aesculap 
TBS-Roti-block solution A151.1 Carl Roth 
Tirofiban Aggrastat® MSD 
Thrombin  T7513 Sigma Aldrich 
Triglycerides-GPO-PAP kit 11488872216 Cobas 
Tween
®
 20 P1379 Sigma-Aldrich 
Xylol/Xylenes 582698 Sigma Aldrich 
Tris-(hydroxymethyl)-aminomethan 2449.3 Carl Roth 
12-Well Plate 3512 Coring 
 Antibodies 3.1.3
Main Antibodies Clone  Manufacturer 
anti-CD41 PE 558040 BD Pharmingen 
anti-CD41 FITC MWReg30 eBioscience  
anti-CD31 eFluor®450 390 eBioscience 
anti-CD45 eFluor®450 30-F11 eBioscience 
anti-CD115 PE AFS98 eBioscience 
anti-ESAM AB4319 Merck Millipore 
Anti-Von Willebrand Factor A0082 Dako 
anti-mouse IgG DyLight 550 ab96880 Abcam 
anti-JAM-A AF488 H202-106 AbD Serotec 
anti-JAM-C PE FAB7050P R&D systems 
anti-human/mouse CD3 A0452 Dako 
anti-human/mouse SMA 1A4 Dako 
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anti-Ly6G PerCP-Cyanine 5.5 RB6-8C5 eBioscience 
anti-mouse MAC-2 CL8942AP Cedarlane 
anti-mouse phosphp-Src (Y418) eFluor660 50-9034-41 eBioscience 
anti-phosphotyrosine  4G10 Merck Millipore 
anti-rat IgG DyLight 488 ab96887 Abcam 
anti-rabbit IgG DyLight 650 ab96926 Abcam 
   
3.2 Methods 
 Mouse models  3.2.1
Mice carrying cre-recombinase under the control of platelet factor 4 (PF4)-promoter were 
a gift from Dr. R.C. Skoda, University Hospital Basel
184
 and were backcrossed in an 
apolipoprotein e (apoe)-deficient background (C57Bl/6) at least ten generations. These 
mice were crossed with JAM-A
flox/flox
apoe
–/–
 mice to obtain platelet-specific        
(tr)JAM-A–/–apoe–/– mice40. Littermates not containing the PF4-cre transgene were used 
as (tr)JAM-A
+/+
apoe
–/–
 controls. All animal experiments were approved by local 
authorities (Regierung von Oberbayern, Munich, Germany). In atherosclerosis research, 
mice were put on high fat diet (HFD, 21% fat, 19.5 % casein, 0.15% cholesterol, ssniff, 
Soest, Germany) for 2, 6 or 12 weeks. For neointimal formation research, mice were put 
on HFD for 1 week before and 2 weeks or 4 weeks after wire-injury operation. 
 Wire-injury in mouse carotid artery 3.2.2
The wire-injury in carotid artery of trJAM-A
+/+
apoe
–/–
 and trJAM-A
–/–
apoe
–/–
 mice is to 
denudate endothelium completely without internal lamina broken38. After mouse 
anesthesia (ketamine 80 mg/kg and medetomidine 0.3 mg/kg), ointment is applied to the 
eyes to prevent cornea drying. The mouse was fixed on a heating plate (tempcontrol 37-2 
digital) at 37 ˚C. Following midline neck incision, the left carotid artery and branches 
were exposed under Stereomicroscope (Stemi: 2000-c linked with the KL 1500 LCD; 
Zeiss). The left common carotid artery and internal and external carotid arteries were 
ligated proximally using 7/0 surgical suture (Serag Wiessner, IO 051391) without tying 
off. Proper suture tension is just for interrupting blood flow. Additional suture was added 
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around distal external carotid artery near bifurcation without tying off. After crosscutting 
a very small hole on external artery between those 2 sutures around the external artery, a 
flexible angioplasty guide-wire with 0.36mm diameter was inserted into common carotid 
artery and advanced about 1 cm. Complete and uniform endothelial denudation was 
achieved by 3 passes back and forth along common carotid artery and with 3 times of 
rotating motion. The wire must move freely and should not get caught at a hole in the 
vessel during motion. After injury, the proximal and distal sutures around external carotid 
artery were tied off and other sutures were moved out gently. The blood flow recovered 
to flow across the carotid artery. To check carotid artery whether clotting, the common 
carotid artery can be monitored for pulsation and color of blood. The skin incision was 
closed by two suture clips (Aesculap, BN507R). After operation, mice were injected 
antagonist (antiamzolhydrochlorid, 0.03mg/kg) to recovery and then put on HFD for 2 
weeks or 4 weeks. 
 Mouse blood collection and analysis 3.2.3
Mice were anesthetized and blood was retro-orbitally collected into EDTA-coated tubes 
(sarstedt, 41.1504.005) for cell counts, plasma isolation, flow cytometry or two-photon 
laser scanning microscopy experiment. Blood was collected into citrate-coated tubes 
(sarstedt, 41.1506.005) for platelet function assessment (platelet aggregation assay). Cell 
counts and mean platelet volume (MPV) were measured using an automated hematology 
analyzer (scil Animal Care). 
3.2.3.1 Leukocytes isolation 
Mice blood was taken from retro-orbital plexus into citrate-coated tubes and centrifuged 
at 1600 rpm for 10 minutes with break (Eppendof, Centrifuge 5415 R). The supernatant 
was taken out without any erythrocytes, just yellow supernatant for platelet isolation. 1ml 
erythrocytes-lysis buffer (8.4g NH4Cl, 0.84g NaHCO3, 1L H20, pH=7.2-7.6, RT) was 
added to the rest (all other cells in the pellets) and then transferred into labeled FACS 
tubes (BD Falcon, Cat.352052) with additional 2 ml erythrocytes-lysis buffer. After 
incubation for 5 min, the sample was centrifuged at 300 g for 5 minutes with break 
(Thermo Scientific, Heraeus® Multifuge® 3S-R Centrifuge). The supernatant was 
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dumped. The pellets were re-suspended in new 3 ml erythrocytes-lysis buffer. These lysis 
steps were repeated twice until pellet turns white. When all the erythrocytes are lysed, the 
pellets are peripheral blood mononuclear cells (PBMCs) for flow cytometry. 
3.2.3.2 Platelet isolation 
Mice platelets were isolated and washed by centrifugation as described
185
. The 
supernatant separated with leukocytes above was centrifuged at 1000 rpm for 6 minutes 
without break (Thermo Scientific, Heraeus® Multifuge® 3S-R Centrifuge). The 
supernatant (Platelet Rich Plasma, PRP) was saved and added citrate buffer (80mM 
sodium citrate tribasic, 52mM citric acid, 183mM glucose, filled and stored at 4˚C). The 
working volume of citrate buffer is 1/25 (v/v) of whole solution volume. Then, the 
sample was centrifuged at 5600 rpm for 5 minutes with break. The supernatant was 
discarded and the pellet was re-suspended in 200µl PBS with 1/25 citriate buffer for 
platelet experiments. 
3.2.3.3 Plasma isolation 
Mice blood was taken from retro-orbital plexus into EDTA-coated tubes and centrifuged 
at 1500 rpm for 15 min. The supernatant (platelet-rich-plasma, PRP) was taken out and 
centrifuged again at 13000 rpm or 5 min. The supernatant (platelet-poor-plasma, PPP) 
was stored in -20˚C. 
 Mouse organ samples collection and process 3.2.4
1) Dissection:  
Mice were anesthetized and blood was retro-orbitally collected in citrate-coated 
tubes. Dissection was done under stereomicroscope (Leica S6) to expose mice 
hearts and vasculature. A catheter was inserted into left ventricle and linked a 
syringe to perfuse cold PBS and cold 4% buffered formaldehyde (PFA, Carl Roth, 
Karlsruhe, Germany), as least 5ml, into mouse circulation. Exclusively, if the 
artery is prepared for protein, DNA or RNA extraction, only cold PBS is used 
without PFA.  
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2) Fixation:  
If necessary, the aorta and carotid arteries were carefully excised without 
peripheral tissues, especially fat tissue. Heart into Eppendorf 
® 
Tube, carotid 
arteries straightly in a small tissue cassette coated inside with paper tissue and 
aorta on a plastic plate using needles to fix, all were put overnight in 4% PFA.   
3) Dehydration and embedding:  
After fixation, the hearts were cut off in the middle and put in tissue cassettes. 
Then, hearts and carotid arteries were placed into histokinate (Leica, ASP200S) 
for dehydration procedure automatically following dehydration solutions 70%, 
70%, 96%, 96%, 100%, 100% to 100% ethanol. Then, the samples were 
immersed in xylene and covered with paraffin. At last, samples were embedded in 
embedding machine (Leica, EG1160) to form paraffin blocks. Carotid arteries 
should be kept standing up straightly in a mental chamber full with melted wax. 
Heart should be put the apical side to the bottom of the mental chamber. 
4) Tissue serial sections:  
The paraffin blocks were cut in sectioning machine (Leica, RM2155). The aortic 
root with 3 valves up 300μm length was cut into 4µm transverse section as each 
piece and left common carotid artery up to 1cm from bifurcation was cut and 
prepared for histology analysis. 
 Histological staining  3.2.5
3.2.5.1 EVG staining 
Elastica van Gieson (EVG) staining kit (Morphisto, Art.-Nr.12739) is used to 
demonstrate elastic fibers in tissue sections for plaque or neointimal area quantification. 
The plaques in aorta roots and neointima in injured carotid arteries were visualized and 
quantified by Leica Qwin Imaging software (Leica Microsystems, Wetzlar, Germany). 
The paraffin sections were chosen out intermittently from each mouse and were 
submerged in the following solutions for de-paraffinization: xylol for 15 minutes in twice, 
ethanol for 5 minutes twice, 96% ethanol for 5 minutes, 70% ethanol 5 minutes and then 
washed in PBS for 5 minutes. The deparaffinized sections were then stained in the 
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following solutions: incubated in Resorcin-Fuchsin (staining elastic fibers) for 20 minutes, 
rinsed for 1 minute in running tap water, incubated for 20 minutes in Weigert's iron 
hematoxylin solution (staining nuclei), rinsed for 10 minutes in running tap water, put in 
1% Hydrogen chloride/70% ethanol solution for 10 seconds (color differentiation), 
washed for 5 seconds in water, incubated in Van Gieson's Solution for 1 minute (staining 
connective tissue), washed in water for 5 seconds, and then incubated in 96% ethanol for 
5 minutes in twice, Isopropanol for 2 minutes, xylol for 5 minutes in twice. The sections 
were covered with mounting solution (Roti-HistoKit II, Carl Roth GmbH) and pictures 
were taken under microscopy (Leica DM RBE). The areas for plaque and aortic root, 
carotid artery lumen and internal and external elastic lamina were measured by Lica 
software (Leica Application Suit V4).  
3.2.5.2 Aortic oil-red-o staining 
The oil-red-o staining was used to quantify aortic plaque in en face. The oil-red-o 
stocking solution was prepared as 1g oil-red-o powder dissolved in 200ml 99% 
isopropanol. The working solution was made up freshly from the stock solution each time: 
75ml stocking solution was diluted with 50ml distilled water and stood for 1 hour, then 
filtered with filter paper. 
After dissection of complete aorta, from aortic root to iliac branch, the aorta is 
longitudinally opened and stapled on a black plastic plate by small needles in 4% PFA for 
overnight. In the next day, aortic adventitial tissue was striped gently and completely. 
Then, the aorta was dipped in 60% isopropanol for 10 times. After that, aorta was 
incubated in the oil-red-o working solution for 15 min. Then, the excess oil-red-o 
solution was removed by dipping the sections 10 times in 60% 2-propanol. The aorta was 
moved onto glass slide and mounted with glycerol (Cat.3783.5, Carl Roth). The pictures 
were taken in a series from a complete aorta under 2.5x objective magnification of 
microscope (Leica DM RBE). The pictures of different parts of the aorta were merged to 
construct en face aorta using photoshop software. The percentage of plaque in whole 
aorta area was quantified using by Lica Microsystems (Leica Application Suit V4). 
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3.2.5.3 Immunofluorescence staining 
Immunofluorescence (IF) staining was used to test JAM-A, CXCL4 and CCL5 
expression in platelets and cell composition in plaque and neointima, such as MAC2
+
 
macrophage, CD3
+
 T cell, α-SMA
+
 smooth muscle cell (SMC) and von Willebrand 
Factor (vWF) staining.  
IF staining of platelet 
Isolated platelets as described185 from mice blood was fixed and permeabilized with 
500µl Cytofix/Cytoperm (BD Bioscience, 554714) for 20 minutes. After centrifuged 5 
minutes at 2200rpm, the pellet was re-suspended in 250 µl 1x Perm/Wash Buffer (BD 
Bioscience, 554714). This washing step was repeated. Primary Antibodies, anti-CXCL4 
(R&D Systems, Minneapolis, MN) and anti-CCL5 antibodies (both R&D Systems, 
Minneapolis, MN), were incubated for 2 hours at room temperature in the dark. Then, 
washing step was followed. Secondary antibodies conjugated with DyLight®-488, -550 
or -650 (all Abcam, Cambridge, UK) were incubated for 1.5 hours at room temperature in 
the dark. After washed twice, the pellet was re-suspended in 100µl PBS. 20 µl of platelet 
suspension was mounted on the glass slide with Vectashield mounting medium (Vector 
Labs). The pictures are taken under fluorescence microscope (Leica DM 6000) with a 
monochrome digital camera (Leica DFC365 FX). 
IF staining of plaque and neointima 
The sections of aortic root and injured carotid arteries were deparaffinized as the same as 
in EVG staining protocol. Then, heat-induced antigen retrieval was done. The samples 
were boiled at 180 watt in 1 x target retrieval solution (Dako, S1699) by microwave and 
then cooled down for at least 20 minutes at room temperature. After antigen retrieval, the 
samples were put in distilled water for 5 minutes, then in PBS for 5 minutes. The liquid 
around sections was removed on the slide very carefully with a paper towel without 
touching the sections (the sections were kept moisture in the whole procedure). Then, 
blocking non-specific binding to the antibodies, for example, the secondary antibody was 
produced from goat, so the blocking solution was 10% goat serum (Dako, X0907) diluted 
in PBS and 50µl of the blocking solution was put on each sample for 20 minutes at room 
temperature. Then, the liquid around samples was removed as before. The first antibodies 
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cocktail were incubated with samples. In this experiment, rat anti-mouse MAC-2 
(2.5µg/ml, CL8942AP, Cedarlane) and rabbit anti-human CD3 (2.7µg/ml, A0452, Dako) 
were diluted in 0.5 % goat serum/PBS and added on the samples for incubation over 
night at 4°C in humid chamber. On the next day, samples were washed in PBS 3 times. 
Then, incubation with secondary antibodies cocktail: the liquid around was removed. In 
this experiment, goat anti-rat IgG DyLight 488 (5µg/ml, ab96887, Abcam) and sheep 
anti-rabbit DyLight 650 (5µg/ml, ab96887, Abcam) were diluted in 0.5% goat 
serum/PBS and incubate for 45 min at room temperature in dark. For smooth muscle cells 
staining, the antibodies are mouse anti-human smooth muscle actin (1:100 dilution, clone 
1A4, Dako) incubated for 1 hour and goat anti-mouse IgG DyLight 550 (5µg/ml, 
ab96880, Abcam) incubated for 1 hour. The same procedure is used in von Willebrand 
Factor staining (1:600, Dako, A0082). At last, after washing in PBS for 5 minutes, 
sections were mounted with Vectashield 4'.6-diamidino-2-phenylindole (DAPI, Hard Set 
Vector Labs) and covered by cover slides. Images were taken under fluorescence 
microscope (Leica DM6000) with the camera (Leica DFC365 FX). The quantification 
was done by Leica Microsystems (Leica Application Suit V4). For background 
assessment, samples were stained instead of primary antibodies with appropriate IgG, 
followed by the secondary antibodies. 
 Multiplate® platelet aggregation measurement  3.2.6
Platelet aggregation in response to adenosine diphosphate (ADP, biopool) and thrombin 
(Sigma Aldrich) was assessed using mouse whole blood within 2 hours after isolation. 
Multiple electrode aggregometry technology in a Multiplate® platelet analyzer was 
according to manufacturer's instructions (Roche Diagnostics, Mannheim, Germany)
186
.  
Blood was collected into EDTA-coated tubes. The multiplate machine was switched on 
and warmed up in 20-30 minutes. Saline solution must be preheated for at least 10 
minutes. The test cells were inserted into the measuring position and attached to sensor 
cables. 150µl 0.9% saline and 150µl blood were added in to the test cell. In some 
experiments, platelets were pretreated with αIIbβ3 integrin antagonist tirofiban 
(Aggrastat®, MSD, 1µg/ml) or the Src kinase inhibitor PP2, SU6656 and KB Src 4 
(Merck Millipore or Tocris, 20, 2.5 and 0.09 µmol/l respectively). The incubation time 
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was 3 minutes. After incubation, the stimulus, such as ADP (0.5µm/l, 1 µm/l, 2µm/l 
respectively) or thrombin (0.021U/ml, 0.11U/ml, 0.51U/ml, 1U/ml respectively), was 
added into the bottom of plastic cells and the test was started. Then, the process of 
platelet aggregation was recorded as curve in image. Platelet aggregation was presented 
as area under the curve in aggregation units (AU), expressed as AU*min, which was 
quantified. 
 Protein extraction 3.2.7
The mice platelets pellets were lysed on ice using the lysis buffer: 50mM tris pH7.4, 
150mM NaCl, 5mM EDTA, 0.1mM DTT, 1% NP-40, 1% CHAPS.  
Protein concentrations of platelet lysis were determined by Bio-Rad protein assay. 
 Immunoprecipitation  3.2.8
Immunoprcipitation was used for testing trJAM-A phosphorylation and related kinase 
involved in trJAM-A de-phosphorylation after platelet stimulation by fibrinogen. Isolated 
washed platelets from mice were incubated on immobilized heat-inactivated Bovine 
serum albumin (BSA, 5mg/ml, SERVA 11922) or mouse fibrinogen (0.1mg/mL, Oxford 
Biomedical Research) for 90 minutes at 37°C, respectively as described
178, 187
. 
The platelets were stimulated on immobilized fibrinogen. The fibrinogen-coated wells 
(Costar
®
12 Well Plates, Corning, 3512) were prepared for stimulating platelets. Mouse 
fibrinogen (1mg/ml stock solution, -80°C, Oxford Biomedical Research) is diluted in 0.9% 
NaCl solution (1:10, working concentration 100μg/ml) and then poured into the wells to 
cover the bottom (about 400µl/well). The control group used 0.5% heat-inactivated BSA. 
After incubation at 37°C for 1 hour, the fibrinogen solution was dropped out and 0.5% 
inactivated BSA blocking solution was added into the wells for 20 minutes at 37°C. Note: 
0.5% BSA working solution should be inactivated previously at 56°C for 45 minutes in 
water bath.  
The isolated platelets was re-suspended in 1/25 (v/v) citrate buffer and measured in the 
automated hematology analyzer (scil Animal Care). Then, platelets were diluted in 1/25 
(v/v) citrate buffer to the concentration 1x 108/ml. In some experiments, protein tyrosine 
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phosphatase inhibitors: IV (20µmol/L), XXXI (30µmol/L), NSC-87877 (0.7 or 10µmol/L) 
and PTP1B inhibitor (8µmol/L), or vehicle (DMSO) were mixed with platelet suspension 
and then pipetted into fibrinogen- or inactivated BSA coated wells during adhesion 
process. The platelets were incubated for 90 minutes at 37°C (cover with the lid) and 
lysed using platelet lysis buffer, as described above.  
JAM-A was immunoprecipitated from platelet lysis, by specific antibody (clone H2O2-
106, AbD Serotec) and protein G-coupled magnetic beads (Dynabeads, Life 
Technologies). It analyzed in western blotting. 
Dynabeads® Protein G binds antibody via their Fc region and was separated using a 
Dynal® magnet. In this experiment, 5µg anti-mouse JAM-A rat monoclonal was diluted 
in 200µl PBS/0.05% Tween 20, with the beads for 1hour. After washing in 200µl 
PBS/0.05% Tween 20, platelet lysis (protein amount 25µg) was added and incubated 
with rotation for 2 hours at room temperature to allow JAM-A to bind to beads-antibody 
complex. After washing bead-Ab-Ag complex three times using 200 µl PBS each time, 
20µl 2x Laemmli Sample Buffer (Bio-Rad, 161-0737) was added to the bead-Ab-Ag 
complex and denatured by heating for 10 minutes at 95˚C. After loading samples, 
western blotting was done. After transferring the proteins to nitrocellulose membrane, the 
primary antibody: anti-phosphotyrosine mouse monoclonal (clone 4G10, Merck 
Millipore) and HRP-conjugated secondary antibody were incubated. After detecting 
protein bands, the anti-phosphotyrosine antibody and secondary antibody were stripped 
from the membrane by the Restore Western Blot Stripping Buffer (Thermo Scientific, 
46430) for 15 minutes at room temperature. After blocking the membrane again, anti-
mouse JAM-A rat monoclonal antibody (clone H2O2-106, AbD Serotec, Düsseldorf, 
Germany) was incubated to perform next western blotting steps. This step was to detect 
the immunoprecipitated protein (JAM-A). 
 Enzyme-linked immunosorbent assays (ELISA) 3.2.9
ELISA is used for testing concentrations of cytokines, chemokines and other antigens 
that are secreted or released into plasma from cells. The coupled antibodies with easily-
assayed enzyme produce a colored substrate indicating a positive reaction.    
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Concentrations of chemokines CXCL4 and CCL5 were measured in platelet poor plasma 
(PPP) from mice fed a HFD for 2, 6 and 12 weeks using Enzyme-linked immunosorbent 
assays (ELISA) kits (both R&D Systems, Minneapolis) accordance with the 
manufacturer´s instructions. The capture antibody specific for the antigen of interest is 
pre-coated onto a 96-well microplate and incubated over night at RT. After aspiration and 
washing 3 times using the 0.05% Tween 20 in PBS, plate was blocked with 1% BSA in 
PBS for 1 h. After washing, the standards or samples were added for binding to capture 
antibody and incubated for 2 h. Following the wash, the detection antibody was added 
and incubated for 2 h at room temperature. After washing, the streptavidin-HRP was 
added and incubated for 20 minutes. Avoid placing the plate in direct light. Last, when 
the substrate solution was added and incubated at room temperature, the reaction yielded 
blue then turns to yellow. After 20 minutes, the stop solution (2N H2SO4) was added. The 
optical density was determined using a microplate reader set to 450 nm/570 nm. A 
standard curve was generated for each set of assayed samples and concentrations of the 
samples were calculated according to standard curve. 
 Enzymatic colorimetric method  3.2.10
Total cholesterol and triglycerides concentrations were analyzed using enzymatic 
colorimetric method (Cholesterol-CHOD-PAP kit and Triglycerides-GPO-PAP kit, both 
Roche Diagnostics) according to the manufacturer’s instructions. 
Prepare the standard, which can be used for cholesterol and triglycerides tests. The stock 
concentration of the standard for cholesterol and triglycerides is 4.35 and 1.44 mm/L, 
respectively. A standard curve was created using 2-fold serial dilutions in 0.9% NaCl. 
Dilute the samples (if necessary) in 0.9% NaCl. Add 50µl of standard or samples and 
150µl reactant reagent per well. Incubate 30 minutes at 37˚C in dark. Cool down for 5 
minutes at RT and microplate reader set to 510 nm. 
  Flow Cytometry 3.2.11
The laser based flow cytometry is a biophysical technology for analyzing cells by their 
size, granularity and allows for detection of protein expression. In a fluid sheath stream, 
one cell at a time passes by an argon laser, which excites fluorescently labeled cells. 
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Measurements of the size (forward scatter) and granularity (sideward scatter) are 
independent from fluorescence signals.  
In this study, the flow cytometry technique was utilized for testing platelet JAM-A, JAM-
C and ESAM expression and counting complex formation in vitro of platelets with 
monocytes or neutrophils. Phosphorylated c-Src was detected using an eFluor®660-
conjugated mouse monoclonal antibody, specific for mouse/human Src phosphorylation 
at tyrosine 418 residue (Y418) (eBioscience). For assessment of JAM-A expression in 
platelets, platelets were labeled with anti-JAM-A AF488-conjugated (AbD Serotec) and 
anti-CD41 PE-conjugated (BD Pharmingen) antibodies. For the platelet-leukocyte 
interactions, isolated platelets were activated by 0.5U/ml thrombin and added to isolated 
erythrocyte-free leukocytes for 20 minutes at 37°C. Finally, cells were stained with anti-
CD41 FITC-conjugated (eBioscience), anti-CD45 eFluor®450-conjugated (eBioscience), 
anti-CD115 PE-Cyanine 7-conjugated (eBioscience) and anti-Ly6G PerCP-Cyanine 5.5-
conjugated (eBioscience) antibodies. In some experiments, platelet-leukocyte interactions 
were analyzed after pretreatment of the platelets with αIIbβ3 integrin antagonist tirofiban 
(Aggrastat®, MSD, 1µg/mL). For the adhesion molecules expression, isolated platelets 
were stained with anti-JAM-A AF488-conjugated (AbD Serotec), anti-JAM-C PE-
conjugated and anti-endothelial cell-selective adhesion molecule (ESAM, Merck 
Millipore), incubated with DyLight®-650-conjugated secondary antibody (Abcam, 
Cambridge, UK). Samples were acquired by flow cytometry (FACSCantoII, BD 
Biosciences) after appropriate compensation settings and analyzed by FlowJo v.10 
software (Tree Star Inc.). 
  Two-photon laser scanning microscopy  3.2.12
Two-photon laser scanning microscopy (TPLSM) is a fluorescence imaging technique 
with deep tissue penetration, efficient light detection and reduced tissue damage
188
. 
TPLSM imaging was performed using a scanner Leica SP5MP (Mannheim, Germany) 
with a pulsed Ti-Sapphire laser (MaiTai HP, Spectra Physics, Mountain View, USA) 
tuned to 800 nm and a 20×NA1.00 water dipping objective (Leica). Emitted fluorescence 
signals were detected using photo-multiplier tubes (PMTs). Image processing was 
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performed using LAS software (Leica) and Image Pro Analyzer v7.0 software (Media 
Cybernetics, Rockville, MD).  
TPLSM was used to analyze platelet adhesion to atherogenic carotid artery wall. The 
trJAM-A
+/+
apoe
–/–
 and trJAM-A
–/–
apoe
–/–
 mice were fed a HFD for 2 weeks. Whole 
blood was retro-orbitally taken from the mice into citrate coated tubes and diluted with 
citrate buffer to adjust platelet count to 1×108 platelets/ml. Carotid arteries were carefully 
explanted, mounted in a customized perfusion chamber and pressurized at physiological 
pressure of 60-80 mmHg. Prior to perfusion, the endothelium was labeled with anti-CD31 
eFluor®450-conjugated antibody (3.5µg/ml, eBioscience) and diluted blood was 
incubated with anti-CD41 FITC-conjugated antibody (3.7µg/ml, eBioscience) for 30 
minutes. Then, blood was perfused along the mounted and pressurized vessel for 10 
minutes at 0.5ml/min. In a second set of experiments, diluted blood was pretreated with 
integrin αIIbβ3 antagonist tirofiban (Aggrastat®, MSD, 1µg/mL) prior to perfusion. The 
first 500µm close to mounting pipettes were excluded due to possible handling damage. 
The corresponding wavelengths was using an acousto-optical beam splitter: 400-440 nm 
for second-harmonic generation (SHG); 460-490 nm (eFluor® 450) and 510-560 nm 
(FITC). Adherent platelets were recorded by TPLSM and counted per field of view of Z-
stack maximum projections (FOV=240µm
2
; voxel size: 0.23 x 0.23 x 1µm
3
). Z-stacks 
were acquired at 0.1 Hz including two-fold frame averaging. 
TPLSM was used to analyze platelet adhesion to wire-injured carotid artery. The trJAM-
A
+/+
 apoe
–/–
 and trJAM-A
–/–
apoe
–/–
 mice were fed a HFD for 1 weeks. Then, the wire-
injury operation was carried out on left carotid artery as described above. One hour after 
wire injury, the injured carotid artery was carefully explanted, mounted in a customized 
perfusion chamber and pressurized at physiological pressure of 60-80 mmHg. To detect 
whether endothelium denudation complete, endothelium was labeled with anti-CD31 
eFlour488 or 450 (3.5µg/ml, eBioscience), and platelet was stained by CD41-PE 
(3.5µg/ml, BD Pharmingen) for 30 minutes. TPLSM was performed using a Leica 
SP5MP system. Emitted fluorescent signals were detected by PMTs tuned for the 
corresponding wavelengths using an acousto-optical beam splitter: 400-440nm for 
second-harmonic generation (SHG); 460-490nm (eFluor® 450), 510-540nm (Alexa 
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Fluor®488) and 570-600nm (PE). Z-stacks were acquired at 0.1 Hz over time including 
two-fold line averaging; One field of view (FOV=330μm2; voxel size: 0.32 x 0.32 x 
1μm3) was recorded. All pictures were processed using LAS software (Leica) and Image 
Pro Analyzer v 7.0 software (Media Cybernetics, Rockville, MD). More than 3 FOVs 
without endothelium signals in each carotid artery were taken for platelet quantification. 
The software (Lecia Application Suite X) constructed 3-D pictures for platelet volume 
measurement and automatically calculate the volume of platelet positive signal. 
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4 Results 
4.1 Adhesion molecule expression in the vasculature 
To investigate the Junctional adhesion molecule A (JAM-A) expression in cardiovascular 
system, we implemented trJAM-A
–/–
apoe
–/– 
mice and compared them to their control 
littermates (trJAM-A
+/+
 apoe
–/–
). The results showed that platelet-specific JAM-A was 
knockout (trJAM-A
–/–
). 
 JAM-A deletion on platelets  4.1.1
Immunofluorescence staining shows CD41 as a marker of platelets and JAM-A expressed 
on isolated platelets from trJAM-A
+/+
apoe
–/–
 mice, but only CD41, not JAM-A, 
detectable on trJAM-A
–/–
apoe
–/–
 mice (Figure 5A). In line, flow cytometry showed that 
CD41 was expressed on isolated platelets from trJAM-A
+/+
apoe
–/–
 mice and trJAM-A
–/–
apoe
–/– 
mice, but JAM-A was not detectable on platelets from trJAM-A
–/–
apoe
–/–
 mice 
(Figure 5B). The percentages of positive platelets expressing JAM-A were depicted in 
upper right quadrant of graphs, which is almost zero from trJAM-A
–/–
apoe
–/– 
mice, 
displaying genetic deletion of JAM-A. These data illustrate efficient knockout of trJAM-
A in trJAM-A
–/–
apoe
–/–
 mice. 
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Figure 5: JAM-A deletion on platelets. JAM-A expression on isolated platelets from 
trJAM-A
+/+
apoe
–/–
 and trJAM-A
–/–
apoe
–/– 
mice were detected by immunofluorescence 
staining (JAM-A: green, CD41: red) and flow cytometry (B). Scale bar=20µm (A). 
Representative pictures of more than 3 independent experiments. 
 JAM-A expression in arterial wall 4.1.2
To localize JAM-A expression in vessel wall, we did immunofluorescence staining in 
carotid arteries from trJAM-A
+/+
apoe
–/–
 and trJAM-A
–/–
apoe
–/–
mice. vWF as a marker of 
ECs was co-localized in intima with JAM-A (Figure 6A). In arterial media, JAM-A 
signal was detectable in SMCs and merged with α-SMA signal (Figure 6B). To quantify 
JAM-A expression in arterial wall, western blot showed JAM-A bands from homogenates 
of aortae or carotid arteries at same level of expression in both groups (data shown in our 
paper). This means that specific genetic deletion of platelet JAM-A did not affect JAM-A 
expression in arterial wall.  
A 
B 
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Figure 6: JAM-A expression in arterial wall. Immunofluorescence images of carotid 
arteries from trJAM-A
+/+
apoe
–/–
 and trJAM-A
–/–
apoe
–/– 
mice. ECs (A, overlays, JAM-A: 
green, vWF: red and nuclei: blue) and SMCs (B, overlays, JAM-A: green, SMCs: red and 
nuclei: blue). Scale bar=20 µm. Independent experiments were repeated more than 3 
times.  
 Related adhesion molecules expression on platelets 4.1.3
To search the effects of trJAM-A deletion on the expression of related adhesion 
molecules, JAM-C and ESAM were stained by fluorescence antibodies and the 
expression levels on platelets were depicted as mean fluorescence intensity by flow 
cytometry. JAM-C was detected on isolated platelets from trJAM-A
+/+
apoe
–/–
 and trJAM-
A–/–apoe–/– mice and quantification of JAM-C expression on platelets by mean 
fluorescence intensity showed no significant difference between trJAM-A
+/+
apoe
–/–
 and 
A 
B 
Results 
47 
 
trJAM-A
–/–
apoe
–/– 
mice (Figure 7A). Although ESAM expression on platelets was 
showed a slight decrease trend in trJAM-A
–/–
apoe
–/– 
mice compared with trJAM-A
+/+ 
apoe–/– mice, but there was no significant difference (Figure 7B). Hence, the absence of 
trJAM-A did not affect related adhesion molecules expression on platelets.  
 
Figure 7: JAM-C and ESAM expression on platelets. JAM-C (A) and ESAM (B) were 
stained by fluorescence antibodies on isolated platelets from trJAM-A
+/+
apoe
–/–
 (blue 
curve) and trJAM-A–/–apoe–/– mice (black curve), compared with controls (grey curve) 
and their fluorescence intensity was measured by flow cytometry. N=3 mice per group. 
Fluorescence intensity was quantified and represented as mean±SEM, P values were 
calculated by Student's t-test. 
A 
B 
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4.2 Platelets and white blood cells counts in mouse blood  
To determine effect of trJAM-A deficiency on blood cell populations, blood in EDTA-
anti-coagulated tubes was isolated from trJAM-A+/+ apoe–/– and trJAM-A–/– apoe–/– mice 
fed HFD for 0, 2, 6, 12 weeks. According to table1, platelet number in blood displayed 
no significant difference between trJAM-A
+/+
apoe
–/–
 and trJAM-A
–/–
apoe
–/– 
mice 
(P<0.05), but platelet count increased with the course of HFD. 
Mean platelet volume (MPV) as a measurement of average platelet size in blood indicates 
platelet production in bone marrow. Once MPV is higher, it means the body is producing 
more platelets. Table 1 showed that MVP was in normal range (4.6-7.3 femtoliter) and 
there was no significant difference between trJAM-A
+/+
apoe
–/–
 and trJAM-A
–/–
apoe
–/– 
mice (P>0.05) at different time points of HFD.  
The number of white blood cells showed stable and little variation between trJAM-A
+/+ 
apoe
–/–
 and trJAM-A
–/–
apoe
–/– 
mice (P>0.05) fed HFD for 0,  2, 6 or 12 weeks. Among 
them, the populations of lymphocytes, monocytes and neutrophils displayed no 
significant difference after platelet JAM-A deletion (P>0.05).  Hence, trJAM-A 
deficiency did not alter the numbers of white blood cells in blood. 
genotype platelets MPV WBC lymphocytes monocytes neutrophils 
trJAM-A+/+, w/o HFD 386±148 6.57±0.35 5.08±0.85 5.25±0.60 0.225±0.03 1.63±0.23 
trJAM-A–/–, w/o HFD 499±157 6.00±0.17 5.50±0.15 5.73±0.07 0.303±0.03 1.47±0.15 
p-value 0.63 0.23 0.22 0.38 0.09 0.62 
trJAM-A+/+, 2w HFD 719±36.9 6.00±0.05 6.23±0.48 4.56±0.39 0.231±0.03 1.44±0.09 
trJAM-A–/–, 2w HFD 766±64.9 5.97±0.06 6.18±0.38 4.47±0.25 0.241±0.03 1.48±0.19 
p-value 0.56 0.66 0.94 0.83 0.81 0.40 
trJAM-A+/+, 6w HFD 765±130 6.67±0.31 4.75±0.67 3.18±0.25 0.167±0.07 1.40±0.43 
trJAM-A–/–, 6w HFD 839±125 6.66±0.41 5.24±0.38 3.66±0.26 0.211±0.03 1.38±0.14 
p-value 0.78 0.71 0.24 0.26 0.21 0.26 
trJAM-A+/+,12w HFD 947±124 6.76±0.17 4.84±0.47 3.03±0.33 0.193±0.03 1.62±0.02 
trJAM-A–/–,12w HFD 1286±146 6.45 ± 0.13 4.40 ± 0.46 2.77 ± 0.28 0.164 ± 0.03 1.46 ± 0.17 
p-value 0.09 0.18 0.37 0.58 0.47 0.57 
 
Table 1: Platelet, mean platelet volume (MPV) and white blood cell counts (WBC). 
The whole blood was isolated into EDTA tubers from trJAM-A
–/–
apoe
–/–
 and trJAM-
A
+/+
apoe
–/–
 mice fed without (w/o) HFD and with HFD for 2 weeks (2w), 6 weeks (6w), 
12 weeks (12 w). Values are shown as (mean ±SEM)*109 cells/L blood, except MPV as 
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(mean ±SEM)*femtoliter. N=7-14 mice per group and all P values were calculated by 
Student's t-test. 
4.3 Lipid metabolism after platelet–JAM-A deletion 
All mice were used in this project with apoe gene deficiency background, which caused 
hypercholesterolemia as the main driving force of lesion growth. Lipid metabolism 
indicated by plasma levels of cholesterol and triglycerides was measured. The data 
showed that there was no significant difference (P>0.05) between trJAM-A
–/–
apoe
–/–
 and 
trJAM-A
+/+
apoe
–/–
 mice fed HFD for 2 weeks or longer.  
genotype cholesterol (mg/dl) triglycerides (mg/dl) 
trJAM-A
+/+
apoe
–/–
, 2w HFD 984 ± 132 164 ± 40.9 
trJAM-A+/+apoe–/–, 2w HFD 1105 ± 125 141 ± 20.5 
p-value 0.51 0.62 
trJAM-A
+/+
apoe
–/–
, 6w HFD 918 ± 132 165 ± 31.5 
trJAM-A
+/+
apoe
–/–
, 6w HFD 951 ± 161 184 ± 48.8 
p-value 0.88 0.96 
trJAM-A
+/+
apoe
–/–
,12w HFD 1222 ± 121 178 ± 26.5 
trJAM-A
+/+
apoe
–/–
,12w HFD 1349 ± 146 222 ± 30.5 
p-value 0.51 0.29 
   
Table 2: Plasma cholesterol and triglyceride levels. Plasma was isolated from  trJAM-
A–/–apoe–/– and trJAM-A+/+apoe–/– mice fed HFD for 2 weeks (2w), 6 weeks (6w) and 12 
weeks (12 w). The levels of cholesterol and triglyceride in plasma are expressed as (mean 
±SEM)*mg/dl. N=7-13 mice per group and all P values were calculated by Student's t-
test.  
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4.4 JAM-A deficiency results in platelet hyperreactivity  
 JAM-A deficiency increases platelet aggregation  4.4.1
To assess platelet aggregation upon activation, multiplate was used to measure platelets 
aggregation under agonist stimulation. Whole blood was isolated retro-orbitally from 
trJAM-A
+/+
 apoe
–/–
 and trJAM-A
–/–
apoe
–/–
 mice into citrate-coated tubes. After dilution, 
blood was added agonist, such as thrombin and ADP, and measured under multiplate. 2 
curves per sample (as internal control) depicted platelet aggregation progress and area 
under the curves as aggregation degree (Figure 8A, B). Under lower concentrations of 
thrombin, from 0.02 U/ml to 0.5 U/ml, JAM-A
–/–
apoe
–/–
 platelets aggregated faster and 
the degree showed significantly elevated, compared with JAM-A
+/+
apoe
–/–
platelets, but 
there was no significant difference under 1U/ml thrombin (Figure 8C). Similar results 
were displayed under ADP stimulation (Figure 8D). The enhanced aggregation to 
different agonists revealed JAM-A
–/–
apoe
–/–
platelet hyperreaction, which was consistent 
with previous findings
181, 182
. These results suggest that JAM-A acts an endogenous 
inhibitor of platelet function. 
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Figure 8: Platelet hyperreactivity in trJAM-A
–/–
apoe
–/–
 mice.  Representative images 
of thrombin activation (0.5 U/mL) to JAM+/+apoe–/– (A) and JAM-A–/–apoe–/– platelets 
(B). Platelet aggregation due to thrombin (C) and ADP (D) activation is presented as area 
under the curve in aggregation units (AU) in 5 minutes, expressed as (mean ±SEM) 
AU*min. N=8-15 mice per group. P<0.05 showed significant difference and all P values 
were calculated by ANOVA with Tukey's post test. 
 JAM-A negatively regulates platelet activity through Integrin αIIbβ3 4.4.2
Previous observations have shown that platelet aggregation is mediated by integrin 
αIIbβ3, which bind with vWF or fibrinogen triggering outside-in signaling. To address 
whether the hyperaggregation of JAM-A
–/–
apoe
–/–
 platelets was also mediated by integrin 
αIIbβ3, its specific antagonist tirofiban was used. After tirofiban inhibition, the 
aggregation of JAM-A–/–apoe–/– platelets was suppressed under 0.5 U/mL thrombin 
stimulation (Figure 9A, B) and quantification of areas under the curves showed 
significantly decrease (P<0.05, between 2 black bars in Figure 9C). Notably, the 
A B 
C 
D 
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enhanced aggregation of JAM-A
–/–
apoe
–/–
 platelets (P<0.01, Figure 9C left) was 
normalized by tirofiban to the level of JAM-A
+/+
apoe
–/–
 platelets, as there was no 
significant difference between JAM-A+/+apoe–/– platelets and JAM-A–/–apoe–/– platelets 
(P>0.05, Figure 10C right). To further validate this observation, ADP stimulated platelets 
also showed similar results (Figure 10D).  Tirofiban dramatically suppressed JAM-A
–/–
apoe
–/–
 platelet aggregation under ADP activation (Black bars) and showed no significant 
difference with JAM-A
+/+
apoe
–/–
 platelets (P>0.05, Figure 10D right). These data indicate 
that integrin αIIbβ3 mediates hyperreaggregation of JAM-A–/– apoe–/– platelets. 
 
Figure 9: Integrin αIIbβ3 controls platelet activity.  Representative images of 
thrombin (0.5 U/mL) activation (A) and tirofiban (1 µg/mL) inhibition (B) to JAM-A–/–
apoe
–/–
 platelets are shown. Curves in the images recorded the process of platelet 
aggregation. Aggregation of JAM-A
+/+
apoe
–/–
 and JAM-A
–/–
apoe
–/–
 platelets activated by 
A B 
C D 
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thrombin(C) or ADP (D) in absence or presence of tirofiban is presented as area under 
the curve in aggregation units (AU), expressed as (mean ±SEM) AU*min. N=8-15 mice 
per group and all P values were calculated by ANOVA with Tukey's post test. 
 JAM-A inhibits c-Src activity in integrin αIIbβ3 outside-in signaling 4.4.3
After platelet activation, integrin αIIbβ3 conformation converted from its low-affinity 
state to a high-affinity state is referred as inside-out signaling173. Ligand binding to the 
activated integrin triggers cascade signaling events to stabilize platelet aggregates, named 
outside-in signaling
174
. To investigate the downstream molecule cascade of integrin 
αIIbβ3 outside-in signaling, the role of Src kinase in platelet aggregation was assessed by 
multiplate. PP2 as an inhibitor of Src significantly blocked the increased aggregation of 
JAM-A–/–apoe–/– platelets, compared with JAM-A+/+apoe–/– platelets stimulated by ADP 
(Figure 10A) or thrombin(Figure 10B).  DMSO, as solvent of PP2, was used additionally 
as control. JAM-A
–/–
apoe
–/–
 platelets still showed significant hyperreaggregation 
compared with JAM-A
+/+
apoe
–/–
 platelets (Figure 10A, B), which indicated that DMSO 
did not affect platelet function. These data revealed that Src combined with integrin 
αIIbβ3, confirmed by previous observations181, 182, regulates platelet aggregation. Taken 
together, Src might regulate platelets aggregation in signaling downstream of integrin. 
Src activity was further explored, which is reflected by Src phosphorylation state at 
residue Y418. Under non-activated conditions, the state of Src Y418 phosphorylation in 
isolated JAM-A
–/–
apoe
–/– 
platelets showed no significant difference with JAM-A
+/+
apoe
–/–
 
platelets. Additionally, the quantification of fluorescence intensity of Src Y418 showed 
that JAM-A deficiency did not affect Src Y418 phosphorylation after thrombin 
stimulation (Figure 10C, D), as thrombin activates platelets leading integrin to high 
affinity state through inside-out signaling. The statistic comparison showed no difference 
(P>0.05, Figure 10C, D) suggested that Src activity and JAM-A was not involved in 
integrin αIIbβ3 inside-out signaling. 
As the ligand of integrin αIIbβ3, Fg can trigger integrin outside-in signaling and activate 
platelets. Isolated platelets adhered to BSA- (as control) or Fg-coated dishes and then Src 
Y418 phosphorylation in platelet activation was measured in flow cytometry. In BSA 
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group, there was no significant difference of Src Y418 phosphorylation in platelets with 
or without JAM-A expression. In addition, with and without Fg stimulation, JAM-
A+/+apeo–/– platelets showed no significant difference of Src Y418 phosphorylation 
(Figure 10F, 2 white bars). In contrast, without JAM-A expression, Fg stimulated 
platelets showed higher Src Y418 phosphorylation, as the fluorescence intensity in JAM-
A
–/–
apoe
–/–
 platelets displayed stronger (Figure 10E), and the data showed significantly 
increased in trJAM-A
–/–
apoe
–/–
 mice (P<0.001, Figure 10F). It illustrates that Src activity 
was increased by JAM-A deficiency during integrin ligating to Fg. In another words, 
JAM-A might decrease the thresholds of Src activation in integrin outside-in signaling. 
Taken together, JAM-A deficiency led to platelet hyperreactivity due to elevated Src 
activity in integrin αIIbβ3 outside-in signaling. 
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Figure 10: JAM-A suppressed c-Src activity in integrin αIIbβ3 outside-in signaling.  
Aggregation of JAM-A
+/+
apoe
–/–
 (white bars) and JAM-A
–/–
apoe
–/–
 (black bars) platelets 
A B 
C D 
E F 
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treated with DMSO (as control) or Src inhibitor PP2 (20µM) after activation by 1 µM 
ADP (A) or 0.5 U/ml thrombin (B). Representative flow cytometry histogram (C) of 
phosphorylated c-Src Y418 residue staining in thrombin-activated platelets (red: control, 
blue: trJAM-A
+/+
apoe
–/–
, orange: trJAM-A
–/–
apoe
–/–
) and quantification of phosphorylated 
c-Src mean intensity in non-activated and thrombin-activated platelets was shown (D). 
Representative flow cytometry histogram (E) of phosphorylated c-Src Y418 residue 
staining in adherent platelets to Fg (red: control, blue: trJAM-A
+/+
apoe
–/–
, orange: trJAM-
A
–/–
apoe
–/–
) and quantification of phopho-c-Src mean intensity in platelets adhered to 
BSA or Fg was shown (F). The data represent mean ± SEM. N=4-7 mice per group and 
all P values were calculated by ANOVA with Tukey's post test. 
 PTP1 catalyzes JAM-A de-phosphorylation after platelet activation 4.4.4
In resting platelets, tyrosine phosphorylated JAM-A (p-tyr/JAM-A) maintains c-Src 
inactivity by recruitment of c-Src-inhibiting kinase CSK to integrin αIIbβ3, to form JAM-
A/CSK/c-Src/integrin αIIbβ3 complex. Upon ligation of integrin αIIbβ3, JAM-A is 
dephosphorylated followed by CSK dissociation from the complex and loses the 
maintenance of Src inactivity
2
. How JAM-A is dephosphorylated remains unclear, so we 
performed immunoprecipitation to investigate the related enzymes using human and 
mouse platelets.  
Protein tyrosine phosphates (PTPs) are responsible for tyrosine de-phosphorylation. 
Among 20 PTPs in platelet signaling events, PTPN1 (PTP1B) was shown to associate 
with integrin complex and regulates platelet outside-in signaling
187
.   In human platelet 
lysates, JAM-A and PTPN1 were detectable, but the antibody against phosphotyrosine 
was not able to detect the p-tyr/JAM-A in western blot (data shown in our paper). 
Immunoprecipitation revealed that p-tyr/JAM-A was co-precipitated with JAM-A 
detectable in resting and activated platelets, but it decreased in Fg-activated platelets, 
which was inhibited by broad-spectrum PTP inhibitor IV (Figure 11 A). This suggested 
that JAM-A de-phosphorylation was catalyzed by PTPs after integrin activation. 
To confirm our observation, we performed JAM-A immunoprecipitation using mouse 
platelets under specific PTPs inhibitors (Figure 11B). p-tyr/JAM-A in Fg activated 
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platelets showed obviously decrease versus in resting platelets, which can be reversed by 
broad-spectrum PTP inhibitor XXXI, PTP1 specific inhibitor or 10 µM NSC-87877. 
Interestingly, NSC-87877, an inhibitor of PTPN6 and PTPN11 (SHP1 and SHP2) at 
lower concentration (0.7 µM), did not affect JAM-A de-phosphorylation. At higher 
concentration (10 µM) of NSC-87877 also blocks PTPN1 suppression of JAM-A de-
phosphorylation (Figure 11B). Taken together, PTPN1 might be responsible PTP that 
catalyzes JAM-A de-phosphorylation during Fg-triggered integrin outside-in signaling. 
Other PTPs might be involved in JAM-A de-phosphorylation to a lesser extent.  
Upon these results, JAM-A as a member of CSK/c-Src/integrin αIIbβ3 complex 
negatively regulates integrin αIIbβ3 outside-in signaling. In other words, JAM-A 
deficiency results in platelet hyperreactivity through decreased threshold of c-Src activity 
in platelet outside-in signaling. After integrin activation, JAM-A de-phosphorylation is 
catalyzed by PTPN1. 
 
Figure 11: JAM-A de-phosphorylation by PTPN1 in integrin outside-in signaling.  
Platelets were isolated from human (A) or mouse (B) blood. Representative immunoblots 
of immunoprecipitated JAM-A were from adherent platelets on BSA- or fibrinogen (Fg)- 
coating dishes with PTP inhibitor or vehicle (veh). Antibodies against to phosphotyrosine, 
JAM-A or PTPN1 were used. IgG was used as control. Broad-spectrum PTP inhibitor IV 
(inh.IV) and XXXI (inh. XXXI). NSC-87877 (NSC 0.7 µM) as an inhibitor of PTPN6 
and PTPN11. NSC at concentration of 10 µM blocks PTPN1. PTPN1 specific inhibitor 
was shown as PTPN1-inh. This experiment was repeated 3 times.  
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4.5 Platelet–JAM-A deficiency enhances vascular inflammation 
 Augmented adhesion of JAM-A–deficient platelets to atherogenic 4.5.1
vessel wall 
To study platelet interaction with atherogenic wall under JAM-A regulation, left carotid 
arteries were explanted from trJAM-A+/+apoe–/– and trJAM-A–/–apoe–/– mice fed a HFD 
for 2 weeks and mounted in a chamber for TPLSM ex vivo. After whole blood incubation 
with anti-CD41-FITC antibody and vessel wall labeled with anti-CD31-eFluor450, blood 
was perfused across the lumen of carotid artery (blood and carotid artery from the same 
mouse). TPLSM images demonstrated that endothelium (blue) was intact and not 
damaged by handling. Notably, platelets adhered to endothelium and more JAM-A–/–
apoe
–/–  
platelets adhered to carotid arterial wall, compared to JAM-A
+/+
apoe
–/– 
 platelets, 
according to the absolute JAM-A
–/–
apoe
–/– 
platelet number per field (in certain area). This 
indicates that JAM-A negatively regulates platelet interaction with atherogenic 
endothelial cells (Figure 12A, B).   
To further confirm that JAM-A regulates platelet interaction with atherogenic vessel wall, 
tirofiban, as the specific inhibitor of integrin αIIbβ3 was applied in the perfused blood.  
Tirofiban diminished JAM-A
–/–
apoe
–/– 
platelet
 
adhesion on ECs (Figure 12C). The 
quantification showed that JAM-A–/–apoe–/–  platelets on ECs significantly decreased after 
tirofiban inhibition, compared to JAM-A
+/+
apoe
–/–
 platelets. There is no significant 
difference of adhesion between JAM-A
+/+
apoe
–/– 
 and JAM-A
–/–
apoe
–/– 
platelets inhibited 
by tirofiban, suggesting that tirofiban can inhibit the hyperreactivity of  JAM-A
–/–
 apoe
–/–   
platelets through integrin αIIbβ3 (Figure 12D).  
Upon vitro, ex vivo or vivo experiments, platelet and leukocyte were co-localized on 
inflammatory endothelium and atherogenic vessel wall. Additionally, platelet 
hyperreactivity due to JAM-A deficiency increased platelets and leukocytes adhesion to 
endothelium, indicating increased leukocytes recruitment to atherogenic sites (data are 
published in Karshovska E, Zhao Z et al, Circ Res. 2015 Feb. 13; 116(4):587-99).  
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Taken together, JAM-A deficiency caused platelet hyperreactivity and increased platelet 
adhesion to atherosclerosis-prone endothelium through integrin αIIbβ3. 
 
Figure 12: Increased adhesion of JAM-A
–/–
apoe
–/– 
platelets to atherogenic 
endothelium. TPLSM images of adherent platelets (CD41, green) on endothelium (CD31, 
blue) in carotid arteries ex vivo from trJAM-A
+/+
apoe
–/– 
and trJAM-A
–/–
apoe
–/– 
mice fed a 
HFD for 2 weeks. Isolated left carotid artery labeled with anti-CD31 eFluor®450-
conjugated antibody (3.5µg/ml, eBioscience) from the mouse was mounted in a chamber 
and perfused by its whole blood incubated with anti-CD41 FITC-conjugated antibody 
A 
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(3.7µg/ml, eBioscience) for 30 minutes without (A, B) or with tirofiban (1µg/mL, C). 
Blood was perfused along the mounted and pressurized vessel for 10 minutes at 
0.5ml/min. Background color was from autofluorescence in vessel wall. Adherent platelet 
number per visual field was counted. Each carotid artery was imaged more than 6 fields 
(D). Scale bar=20µm (A, B, C). N=5-8 mice per group and P values were calculated by 
Kruskal-Wallis test with Dunn´s post test. 
 Increased plasma levels of chemokines due to JAM-A–deficient 4.5.2
platelets 
As previous studies, platelets store and release many inflammatory proteins, including 
various kinds of chemokines, such as platelet factor 4 (PF4, CXCL4) and regulated on 
activation, normal T cells expressed and secreted (RANTES, CCL5), which can increase 
recruitment of mononuclear cells to the inflamed vessel wall
82, 189
. Thus, CXCL4 and 
CCL5 were chosen out as the investigated targets in atherosclerosis.  
Immunofluorescence staining showed that CXCL4 was rich on the surface and in 
cytoplasm of platelets and its expression level was higher than CCL5 in JAM-A wild type 
mice (Figure 13A, C). Interestingly, CXCL4 and CCL5 in JAM-A
–/–
 platelets diminished, 
as fluorescence intensity was weaker in JAM-A
–/– 
apoe
–/– 
 platelets compared to JAM-
A
+/+
apoe
–/– 
platelets (Figure 13A, C), indicating that JAM-A deficiency elevated 
chemokines release from platelets.  
Notably, ELISA data showed that CXCL4 concentration in plasma increased in trJAM-
A
–/–
apoe
–/–  
 mice compared to trJAM-A
+/+
apoe
–/– 
mice, significantly in advanced stage of 
atherosclerosis (HFD 12 weeks). As the disease progression, the plasma level of CXCL4 
increased from 2 weeks to 12 weeks HFD in trJAM-A
–/–
apoe
–/– 
mice, while it was stable 
in trJAM-A
+/+
apoe
–/– 
mice (Figure 13B).  
Plasma CCL5 concentration was markedly raised in trJAM-A–/–apoe–/– mice verses in 
trJAM-A
+/+
apoe
–/– 
mice during earlier stages of atherosclerosis (HFD 2 weeks, 6weeks), 
although there was no significant difference at late stage (Figure 13D), indicating that 
trJAM-A deficiency might augment CCL5 secretion from platelets. However, the 
baseline levels of CCL5 and CXCL4 in plasma without HFD showed no significant 
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difference between trJAM-A–/–apoe–/– and trJAM-A+/+apoe–/– mice (data no shown), 
suggesting that the increased CCL5 and CXCL4 in plasma might require HFD co-
stimulation with JAM-A deficiency on platelets.   
These data revealed that trJAM-A deficiency under hyperlipidemia led to intracellular 
CXCL4 and CCL5 release in platelets paralleled with higher levels in plasma during the 
context of atherosclerosis. Taken together, it implied that JAM-A deficiency might 
augment chemokines (CXCL4 and CCL5) secretion from platelets into plasma. In turn, 
increased chemokines might recruit more leukocytes to atherosclerosis-prone sites. 
 
Figure 13: Role of platelet–JAM-A in Chemokines release. Representative images of 
CXCL4 in platelets from trJAM
+/+
apoe
–/–
 and trJAM
–/–
apoe
–/–
 mice fed 12 weeks (A). 
CCL5 staining in platelets from trJAM+/+apoe–/– and trJAM–/–apoe–/– mice fed 2 weeks (C). 
Scar bar: 20µm. Each experiment was repeated more than 3 times. The levels of CXCL4 
and CCL5 in platelet poor plasma isolated from trJAM
+/+
apoe
–/– 
and trJAM
–/–
apoe
–/– 
 
mice fed 2 weeks, 6 weeks or 12 weeks (B, D). CXCL4 concentration in plasma 
represents (mean±SEM) µg/mL and CCL5 concentration in plasma represents 
(mean±SEM)*102 pg/mL. N=7-14 mice per group. All P values were calculated by 1-way 
ANOVA with Bonferroni´s post test.  
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 Enhanced interactions of JAM-A–deficient platelets with leukocytes 4.5.3
Previous studies have found that activated platelets can form complexes with leukocytes 
in cardiovascular disease
105, 190, 191
. To address whether JAM-A
–/–
apoe
–/– 
platelets 
hyperreactivity contributes to the interactions with leukocytes, isolated platelets were 
activated by thrombin and then incubated with leukocytes. Flow cytometry measured the 
percentage of complexes, platelet-monocyte (Figure 14A) and platelet-neutrophil (Figure 
14B) in total leukocytes and found that JAM-A
–/–
apoe
–/– 
platelets combined to leukocytes 
more than JAM-A
+/+
apoe
–/– 
platelets. The statistic results showed that complex 
percentage of JAM-A
–/–
apoe
–/–
 platelets with monocytes was significantly elevated, 
compared to JAM-A+/+apoe–/– platelet-monocyte complexes. To further explore the 
molecular mechanisms, tirofiban blocking integrin αIIbβ3 diminished the enhanced 
interactions between JAM-A–/–apoe–/– platelets and monocytes (Figure 14A, C). The 
similar results of platelet-neutrophil complex formation were also found (Figure 14B, D). 
These data indicates that trJAM-A deficiency can promote platelet-leukocyte complex 
formation, which can facilitate leukocyte tethering on endothelial cells190, 191. It implies 
that platelet hyperreactivity due to JAM-A deficiency might increase leukocyte 
recruitment from blood to the atherogenic sites through platelet-leukocyte complex 
formation in blood circulation. 
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Figure 14: platelet–JAM-A deficiency enhanced platelet-leukocyte complex 
formation. Representative flow cytometry histograms of platelet (CD41
+
)-monocyte 
(CD115
+
) interactions (A) and platelet-neutrophil (ly6G
+
) complexes (B) in absence or 
presence of tirofiban (1 µg/ml). Platelets were activated by thrombin (0.5U/ml) and then 
incubated with isolated leukocytes (CD45
+
). Quantification of complexes percentage was 
shown (C, D). Data: mean±SEM (n=7-14) and all P values were calculated by 1-way 
ANOVA with Bonferroni´s post test. 
A 
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4.6 Platelet–JAM-A deficiency accelerates atherosclerosis 
To investigate the gain-of-function of JAM-A–deficient platelets during atherosclerotic 
progress, the plaques were assessed in trJAM-A
–/–
apoe
–/– 
and trJAM-A
+/+
apoe
–/–
 mice fed 
HFD for 2 weeks, 6 weeks or 12 weeks.  
 JAM-A–deficient platelets propagate aortic atherosclerosis 4.6.1
To clarify the effect of trJAM-A deficiency in atherosclerosis, aortic plaques were 
measured to assess atherosclerotic burden.  trJAM-A
–/–
apoe
–/– 
and trJAM-A
+/+
apoe
–/– 
mice were fed for 2 weeks, 6 weeks or 12 weeks to represent different stages of plaque 
formation. After HFD, isolated complete aorta from each mouse was stained by oil-red-O 
to visualize plaque area. According to the representative pictures of aortas, the plaque 
size enlarged progressively with time of HFD (Figure 15A, B, C). The quantification 
showed that plaque formation in aortic arch was significantly increased after 2 weeks 
HFD in trJAM-A
–/–
apoe
–/– 
mice (Figure 15D). Similarly, aortic plaque formation in 
trJAM-A
–/–
apoe
–/– 
mice was significantly enhanced, compared to trJAM-A
+/+
apoe
–/– 
mice 
fed HFD for 6 weeks and 12 weeks (Figure 15E, F). These results suggest the 
atheroprotective role of platelet JAM-A in aortic atherosclerosis.  
 
A B C 
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Figure 15: trJAM-A deficiency augmented aortic atherosclerosis. trJAM-A+/+apoe–/– 
and
 
trJAM-A
–/–
apoe
–/– 
mice were fed HFD for 2 weeks, 6 weeks or 12 weeks. Oil-red-o 
staining visualized plaques in complete aortas (A, B, C). Percentages of plaque areas in 
aortic arch after 2 weeks HFD (D) and in whole aorta after 6 weeks´ (E) and 12 weeks 
HFD (F) were quantified. Data represents mean±SEM (N=7-12) and all P values were 
calculated by Student´s t-test.  
 Platelet–JAM-A deficiency enhances early-stage atherosclerosis in 4.6.2
aortic root 
To further verify the effects of JAM-A in atherosclerosis,  plaques in aortic roots from 
trJAM-A
–/–
 apoe
–/– 
and trJAM-A
+/+
apoe
–/– 
mice fed HFD for 2 weeks, 6 weeks or 12 
weeks to imitate different stages of atherosclerosis were visualized and quantified. 
According to the representative pictures and the average size of plaques, hyperlipidemic 
mice had grown plaques from 2 weeks to 12 weeks in 2 groups (Figure 16). Importantly, 
trJAM-A deficiency promoted this progression, especially at early stage of 
atherosclerosis, as the quantification showed significant increase of plaque size in trJAM-
A
–/– 
apoe
–/–  
mice compared to trJAM-A
+/+
apoe
–/– 
 mice fed HFD for 2 weeks (Figure 
16A). However, there was no marked difference after 6 weeks and 12 weeks HDF 
(Figure 16B, C). These results suggest that platelet hyperreactivity due to JAM-A 
deletion enhance atherosclerosis, especially at early stage.  
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Figure 16: JAM-A–deficient
 
platelets accelerated early-stage plaque formation in 
aortic root. Representative pictures of EVG staining in aortic root from trJAM-A
–/– 
 and 
trJAM-A
+/+ 
mice fed 2 weeks (A), 6 weeks (B) or 12 weeks (C). Scale bar=500µm. 
Plaque quantification was expressed as size percentage of plaque area in aortic luminal 
area (mean±SEM). N=7-12 mice per group and all P values were calculated by Student´s 
t-test.  
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 trJAM-A absence increases leukocyte infiltration into early-stage 4.6.3
plaques 
The plaque cell composition was analyzed using immunofluorescence staining in aortic 
roots. The number of MAC-2
+
 macrophages in early plaques (2 weeks HFD) displayed a 
marked increase in trJAM-A
–/–
apoe
–/– 
mice, compared to the control group (Figure 17A). 
Similarly, CD3
+
 cells staining revealed significantly higher infiltration of T cells in 
plaques of trJAM-A
–/–
apoe
–/– 
mice, compared with control littermates (Figure 17B).  The 
data suggests that trJAM-A deficiency promotes inflammatory progress at early-stage of 
atherosclerosis. SMCs (α-SMA
+
 cells) in plaque significantly increased in aortic roots of 
trJAM-A
–/–
apoe
–/– 
mice fed 2 weeks HFD (Figure 17C). These increased cell contents in 
plaques contributed to the enhanced atherosclerosis at early stage. 
 
Figure 17: Plaque cell compositions at early stage of atherosclerosis. 
Immunofluorescence staining of MAC-2 (A, green), CD3 (B, pink) and α-SMA (C, red) 
A B C
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in aortic roots from trJAM-A+/+apoe–/– and trJAM-A–/–apoe–/– mice fed 2 weeks HFD. 
Dashed lines represent plaque boundary. Asterisks show aortic lumen and arrows direct 
CD3 positive T cells. Nuclei (blue) were stained by DAPI. Scale bar=100µm. 
Quantifications display the positive cells number in plaque area (n=7-12). P<0.05 
indicates significant difference and all P were obtained by Student´s t-test with (A, C) or 
without (B) Welch correction. The means ± SEM are shown.  
 Platelet–JAM-A deficiency does not alter cell composition in advanced 4.6.4
plaques 
To study whether platelet JAM-A affects plaque phenotype until later stages, the cell 
composition in plaques was quantified in aortic roots in trJAM-A
+/+
apoe
–/–  
and trJAM-A
–
/– 
apoe
–/–  
mice fed 6 weeks or 12 weeks. Platelet JAM-A deletion did not influence 
Mac2
+
 macrophage and CD3
+
 T cells content in plaques. It indicated that relevance of 
platelet JAM-A diminished at later stages of atherosclerosis, compared to early 
inflammatory progress. Additionally, SMCs in plaques also showed no difference in 
trJAM-A
–/–
 apoe
–/–  
mice versus trJAM-A
+/+
 apoe
–/–  
mice (Figure 18).  
Taken together with the observation at early stage (2 weeks), platelet JAM-A inhibited 
atherosclerosis, especially at initial stages, by suppressing inflammatory cell infiltration 
into plaques and SMC accumulation in plaques. However, this contribution declined 
during plaque progression.  
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Figure 18: Plaque cell composition in advanced plaque. Immunofluorescence staining 
of MAC-2 (A, green), CD3 (B, pink) and α-SMA (C, red) in aortic roots from trJAM-
A
+/+
apoe
–/–  
and trJAM-A
–/–
apoe
–/–  
mice after 12 weeks. Dashed lines represent plaque 
boundary.  Asterisks show aortic lumen and arrows direct CD3 positive cells. Nuclei 
(blue) were stained by DAPI. Scale bar=200µm (A, C) and 100µm (B). Quantifications 
display the positive cells number in plaque area (n=7-12). P<0.05 indicates significant 
difference and all P were obtained by Student´s t-test. The means ± SEM are shown. 
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4.7 Platelet–JAM-A deficiency facilitates neointimal formation  
It has been found that JAM-A deficiency reduced neointimal lesion formation and 
monocyte infiltration in atherosclerosis-prone mouse model with somatic JAM-A 
deletion
39
. But there is no evidence about cell-specific role of platelet JAM-A in vascular 
remodeling after acute injury. As platelets are the first cells arriving at inflammatory 
sites
9
, it is important to clarify the importance of platelet hyperreactivity in neointimal 
formation.  
 JAM-A deficiency encourages platelet adhesion on injured arterial wall 4.7.1
To investigate JAM-A
–/–
apoe
–/–  
platelets adhesion on endothelium-denuded vessel wall, 
TPLSM was applied to detect platelets adhesion 1 hour after wire-induced injury in 
carotid arteries ex vivo from trJAM-A
+/+
apoe
–/– 
and trJAM-A
–/–
apoe
–/–  
mice fed 1 week 
HFD. The adherent platelets on artery wall were constructed into 3-D images and 
measured as volume in each field. The intact endothelium in carotid artery was shown as 
CD31 staining (Figure 19A, left), compared to endothelium-denuded artery wall covered 
by platelets labeled with anti-CD41-PE antibody (Figure 19A, middle and right). The 
complete endothelium-denuded area (no CD31 staining) for platelets measurement in 3-D 
image was depicted as schematic diagram from surface and cross-sectional views of 
artery wall (Figure 19B). JAM-A–/–apoe–/– platelets adhesion to the vessel wall increased 
according to 3-D images, compared to JAM-A
+/+
apoe
–/– 
platelets. Statistic data showed 
that JAM-A–/–apoe–/– platelets adhesion to the endothelium-denuded vessel wall was 
significantly increased versus JAM-A
+/+
apoe
–/– 
platelets. 
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Figure 19: JAM-A deficiency improved platelets adhesion to acute injured vessel 
wall. 3-D images from HPLSM show normal and endothelium-denuded carotid arteries 
(A) 1hour after injury in trJAM-A
+/+
apoe
–/–  
and trJAM-A
–/–
apoe
–/–  
mice fed 1 week HFD. 
Endothelium labeled by anti-CD31-eFluor450 antibody (Blue) and platelets stained by 
anti-CD41 antibody (Red). Green color is from autofluorescence in the vessel wall. 
Schematic diagrams from the surface and cross-sectional views of artery represent 
measurement of adherent platelets (B). Scale bar: 50µm. Quantification of platelet 
volume (µm
3
) in each certain field was showed (>3 fields/mouse). Data: the average 
volume in each field per mouse expressed as mean±SEM. N=4 mice per group. P<0.05 
indicates significant difference and P values were obtained by Student´s t-test.  
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 Promoted neointimal formation at early stage by platelet–JAM-A 4.7.2
deficiency 
Vascular injury causes endothelial denudation and exposure of extracellular matrix, 
which is followed by platelet adhesion, thrombus formation, leukocytes infiltration
16
, and 
SMCs proliferation, migration as well as secretion of extracellular matrix
17
. JAM-A 
deficiency augmented platelets adhesion to the vessel wall after 1 hour injury, which 
might contribute to neointimal formation at early stage. The neointimal formation after 
wire-induced injury 2 weeks in the left carotid artery from trJAM-A
+/+
apoe
–/– 
and trJAM-
A–/–apoe–/– mice was quantified using EVG staining (Figure 20). The data shows 
significantly increase of neointimal formation in trJAM-A
–/–
apoe
–/–
 mice, compared to the 
control group, indicating that trJAM-A might suppress neointimal formation at early-
stage after vascular injury. 
 
Figure 20: Platelet–JAM-A deficiency increases neointimal formation at early stage. 
Carotid artery sections from trJAM-A+/+apoe–/– and trJAM-A–/–apoe–/– mice after wire-
injury 2 weeks were visualized by EVG staining to delineate neointimal lesion (A, B). 
Before 1 week and after 2 weeks of wire-injury, mice were put on HFD. Scale bars: 100 
µm. Neointima was measured and average size was expressed as (mean± SEM) µm
2 
per 
mouse (C). N=4-6. *P<0.05. P values were obtained using two-tailed Student’s t-test. 
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 Platelet–JAM-A does not affect neointimal formation at advanced 4.7.3
stage 
Acute endothelial injury will cause the vessel wall remodeling, characterized by 
neointimal formation. We have found that platelets adhesion increased due to JAM-A 
deficiency in this acute response. To address whether platelets with JAM-A deficiency 
promotes neointimal formation continuously, the neointimal size was quantified after 
wire-induced injury 4 weeks in the left carotid artery from trJAM-A
+/+
apoe
–/– 
and trJAM-
A–/–apoe–/–  mice using EVG staining. The results showed that there was no significant 
difference between two groups (Figure 21), which indicates that the influence of platelet–
JAM-A deficiency was limited at advanced stage of vascular remodeling.  
 
Figure 21: Platelet–JAM-A deficiency did not alter neointimal formation at 
advanced stage. Carotid arterial sections from trJAM-A
+/+
apoe
–/– 
and trJAM-A
–/–
apoe
–/– 
mice after wire-injury 4 weeks were visualized by EVG staining to delineate neointimal 
lesion (A, B). Before 1 week and after 4 weeks of wire-injury, mice were put on HFD. 
Scale bars: 100 µm. Neointima was measured and average size was expressed as (mean± 
SEM) µm2 per mouse (C). N=11-13. NS: no statistically significant difference (P>0.05). 
P values were obtained using two-tailed Student’s t-test.  
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 Platelet–JAM-A deficiency mildly affects neointimal cell composition 4.7.4
We investigated the cell composition in advanced neointimal lesion after platelet–JAM-A 
deficiency. Macrophages and SMCs were visualized by the immunostaining of MAC-2 
and α-smooth muscle actin (α-SMA). The quantification of cell number in plaques 
showed no significant difference (Figure 22A, B). However, the absolute CD3+ cells in 
neimtina significantly increased after platelet–JAM-A deficiency (Figure 22C). To 
address the effect of platelet–JAM-A on re-endothelialization after intimal injury 4 weeks, 
vWF as endothelial cell marker was stained in carotid arteries. The length of vWF 
positive lines in luminal circumferences was measured. The data showed no significant 
difference (Figure 22D). Taken together, trJAM-A deficiency mildly enhanced 
inflammatory cells infiltration into the neointima, especially T cells. The cell composition 
of neointima at early stage remains to be investigated. 
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Figure 22: Platelet–JAM-A deficiency mildly alters neointimal cell composition in 
advanced lesion. Representative pictures and quantifications of MAC-2 (A), α-SMA (B), 
CD3 (C) and vWF (D) stained in left carotid artery sections after wire-induced injury 4 
weeks from trJAM-A
+/+
apoe
–/– 
and trJAM-A
–/–
apoe
–/– 
mice. Neointimal areas were 
demarcated with dashed lines, MAC2- and CD3- positive cells were marked with arrows.  
B 
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Nuclei were stained with DAPI (blue). Scale bar=100µm. The quantification of cell 
composition was expressed as MAC2
+
 or α-SMA
+ 
cells in total neointimal cells. Absolute 
CD3+ cells in neointima were compared. The length percentages of vWF+ lines in luminal 
circumferences were calculated. Data: mean±SEM. N=5-8 mice per group.*P<0.05 
indicates significant difference and P values were obtained by Student´s t-test. 
5 Discussion 
 
Atherosclerosis is characterized a chronic inflammatory disease leading to fatal 
complications such as myocardial infarction, stroke and peripheral artery disease.  During 
disease progression, atherosclerotic plaque is formed by endothelial cell activation, lipid 
accumulation, inflammatory cell infiltration, macrophage and foam cell formation, SMC 
and extracellular matrix accumulation in the intima2, 4. It is well known that platelet 
activation plays a substantial role in vascular inflammation and antiplatelet therapy is 
effective to prevent and treat cardiovascular events
192, 193
. Remarkably, some studies have 
indicated that platelets can function as initiators and propagators of atherosclerosis
60, 77
. 
However, there is little evidence to directly illustrate the role of platelet hyperreactivity in 
vascular inflammation and atherosclerotic formation.  So we implemented mouse models 
with platelet hyperreactivity due to JAM-A deficiency into the context of atherosclerosis, 
demonstrating platelet-mediated increase of vascular disease. We found that platelet-
specific JAM-A (trJAM-A) deficiency caused platelet hyperaggregation under 
hyperlipidemic conditions. To explore the function of JAM-A
–/–
 platelets in 
atherosclerosis, we found increased plasma levels of chemokines and enhanced 
interactions of platelet-leukocyte and platelet-endothelium in trJAM-A
–/–
apoe
–/– 
mice. In 
turn, elevated recruitment of JAM-A
–/–
apoe
–/–
 platelets with leukocytes to inflamed vessel 
wall was demonstrated and eventually led to aggregated atherosclerotic plaque formation 
in trJAM-A
–/–
apoe
–/– 
mice, particularly in early stages, compared to trJAM-A
+/+
apoe
–/–
 
mice. Notably, these pro-inflammatory effects of JAM-A–/–apoe–/– platelets could be 
abolished by inhibition of integrin αIIbβ3 signaling in vitro. 
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Despite atherosclerosis, platelets also play pivotal roles in neointimal formation. 
Activated platelets release cytokines to activate endothelial cells and recruit leukocytes 
into the injured vessel wall37, indicating platelet regulated vascular repair progress. 
Recently, we found that JAM-A has cell-specific role in atherosclerosis
40
 and a previous 
study showed that the globally genetic deletion of JAM-A in apoe-deficient mice 
decreased neointimal hyperplasia
39
, suggesting the role of platelet-specific JAM-A on 
neointimal formation potentially important. According to our data, platelet–JAM-A 
inhibited neointimal formation at early stage (2 weeks), but not at advanced stage (4 
weeks) after vascular acute injury. The mechanism remains to be clarified. 
 
Taken together, the hyperreactivity of platelets due to JAM-A deficiency promotes 
vascular remodeling, especially at early-stage.  
5.1 Platelet-specific JAM-A knockout 
To determinate the efficiency of JAM-A gene knockout in platelet-specific (tr)JAM-A
–/–
apoe–/– mice40, 184, we checked the JAM-A expression on platelets, leukocytes as well as 
in vessel wall (Figure 5,6 and additional data referred to our paper) and found that 
platelet JAM-A was specifically deleted in trJAM-A
–/–
apoe
–/–
 mice without affecting 
JAM-A expression on leukocytes and SMCs. After JAM-A deficiency in platelets, JAM-
C and ESAM expression was not altered (Figure 7), suggesting remaining functions of 
JAM-A–/–apoe–/– platelets unaffected. Additionally, mean platelet volume (MPV) showed 
that platelet production was not altered, as same as leukocyte numbers in blood of trJAM-
A–/–apoe–/– mice (Table 1). Importantly, there was no significant difference in cholesterol 
and triglyceride levels between trJAM-A
–/–
apoe
–/–
 mice and the control group, indicating 
that platelet JAM-A might not affect lipid metabolism. These data revealed that platelet-
specific JAM-A deficiency did not influence the homeostasis in our mice model, which 
rendered the reliability to investigate the role of platelet–JAM-A in vascular remodeling.  
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5.2 JAM-A–deficient platelets gain hyperreactivity  
 
Figure 23: JAM-A inhibiting platelet activation via integrin αIIbβ3 signaling. In 
resting platelets, one complex is formed as CSK–JAM-A–αIIbβ3–c-Src on the cell 
membrane. JAM-A is phosphorylated and recruits CSK to this complex to inhibit c-Src 
activation in cytoplasmic side. After platelet activated by stimuli, such as ADP via 
P2Y1/P2Y12 in mice and thrombin via PAR3/PAR4, the inside-out signaling is triggered 
and induces integrin αIIbβ3 activation for fibrinogen binding, which initiates outside-in 
signaling. Consequently, JAM-A and CSK dissociate from the complex and c-Src is 
activated. After dissociation, JAM-A is dephosphorylated by PTPN1and transduces 
unknown signals into platelet. The activated inside-out and outside-in signaling 
eventually result in platelet shape change, aggregation as well as degranulation via PI3 
kinase-, PLC- and RhoGAP-mediated pathways with increased cytoplasmic levels of 
Ca2+. JAM-A: Junctional adhesion molecular-A. c-Src: Tyrosine-protein kinase. CSK: c-
src tyrosine kinase. PTPN1: Tyrosine-protein phosphatase non-receptor type 1. (This 
pathway bases on the findings of Naik et.al181) 
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Platelets are important player in chronic pathological processes including the 
atherosclerotic remodeling
9
. The interaction of platelet receptors with adhesion 
molecules, such as vWF recptor–GPIb/V/IX and collagen receptor–GPVI, facilitates 
platelet adhesion and activation at sites of inflamed vascular wall
194
, which in turn 
induces inside-out activation of integrins to strengthen the adhesion, including integrin 
αIIbβ3 (GPIIb/IIIa) or α2β1 (GPIa/IIa)
194, 195
. Once the initial signals have been triggered, 
platelets will release a variety of mediators to amply platelets activation, such as ADP, 
and thromboxane A2. Interestingly, on the surface of activated platelets, the formation of 
mature thrombin is triggered and further promotes platelet activation
196
.  These diffusible 
mediators binding to G-protein-coupled receptors (GPCRs), involving 3 major G proteins 
Gq, G13 and Gi, amplify the initial signals
197
. ADP stimulates platelet intracellular 
signaling through G protein-coupled receptors, P2Y1 and P2Y12, whereas thrombin via 
protease-activated G-protein-coupled receptors PAR1/PAR4 (human) or PAR3/PAR4 
(mouse), resulting in platelet shape change, degranulation and multiple platelet/platelet 
interactions (platelet aggregation)
197, 198
. Platelet aggregation is mediated by integrin 
αIIbβ3, which binds various extracellular macromolecular ligands, such as fibrinogen and 
vWF. Signals transduced by αIIbβ3 regulate platelet activity, such as shape change, 
aggregation and granule secretion199-201.  
 
JAM-A deficiency augments platelet aggregation. We used ADP and thrombin at 
different concentrations to investigate platelet activation. JAM-A
+/+
apoe
–/–
 platelet 
activation at low concentrations of thrombin showed no difference (Figure 8C), which 
might be due to the cofactor-assisted PAR activation on platelets, consistent with 
previous observations
202
. Notably, low concentrations of thrombin dramatically 
stimulated JAM-A
–/–
apoe
–/– 
platelet aggregation compared with JAM-A
+/+
apoe
–/–
 
platelets. This result was similar with ADP stimulated platelets (Figure 8). Thus, JAM-A
 
deficiency caused platelets to be easily activated by agonists. Naik and coworkers found 
that genetic ablation of JAM-A in mice enhanced thrombotic function of platelets in vivo 
with increased platelet aggregation
182
. Taken together, JAM-A inhibits platelet function, 
analogous to other adhesion molecules such as endothelial cell-selective adhesion 
molecule (ESAM), which down-regulated platelet aggregation and thrombus 
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formation
203
. In addition, CD31 on platelets suppressed platelet aggregation as its 
crosslinking reduced agonist-induced platelet aggregation
204
 and genetic deletion of 
CD31 in platelets, not in endothelial cells, increased thrombus formation in vivo205. After 
CD31 activation by vWF binding to GPIb/IX/V complex, as a negative feedback loop, 
CD31 in turn suppresses GPIb-initiated platelet signaling responses, thus inhibiting the 
extent of platelet activation and aggregation
206
. 
 
It has been found that JAM-A regulates platelet activity through integrin αIIbβ3 outside-
in signaling
182
. In our study, tirofiban as a specific antagonist to integrin αIIbβ3 reversed 
the hyperaggregation of JAM-A
–/–
apoe
–/–
 platelets to the level of JAM-A
+/+
apoe
–/–
 
platelets (Figure 9). Thus, our data also confirm that JAM-A regulates platelet reactivity 
by inhibiting integrin αIIbβ3. Previous researches showed that some specific protein 
tyrosine kinases and phosphatases might be involved in the downstream of signal 
pathway in platelet activity. Especially, Src family kinases have been found pivotal in 
outside-in signaling in many cell types
207-210
. Thus, c-Src tyrosine kinases activity was 
assessed in our experiments, as it is well known that c-Src binds constitutively and 
selectively to β3 in platelets
178, 211
. Notably, PP2, as an inhibitor of c-Src, reversed the 
hyperreactivity of JAM-A–/–apoe–/– platelets effectively (Figure 10A, B). Furthermore, 
phosphorylation degree of Tyr-418 in the c-Src loop reflects the extent of c-Src activation 
in integrin outside-in signaling
211
. We used soluble thrombin to trigger inside-out 
signaling (without outside-in signaling stimulation) in isolated platelets and found that 
the extent of c-Src Y418 phosphorylation was not affected by JAM-A deficiency (Figure 
10C, D). This data support that c-Src and JAM-A might be not involved in integrin 
inside-out signaling. Conversely, c-Src Y418 phosphorylation was elevated in JAM-A
–/–
apoe
–/–
 platelets after Fg stimulation, which triggers outside-in signaling (Figure 10E, F). 
Taken together, c-Src as the signal molecule transduces outside-in signaling via integrin 
αIIbβ3, which is inhibited by JAM-A in platelets.   
 
JAM-A suppresses c-Src activity on platelets
182
. However, in resting JAM-A
+/+
apoe
–/–
 
and JAM-A
–/–
apoe
–/–
 platelets, there was no significant difference of c-Src Y418 
phosphorylation (Figure 10D, F), indicating that c-Src activity was not stimulated solely 
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due to JAM-A deficiency in resting platelets. In literature, c-Src can become partially 
activated in cell resting state, but not fully activated, after binding to the β3 integrin tail 
through Src homology 3 (SH3) domain211. Additionally, intramolecular interactions of 
SH3 binding to Src homology 2 (SH2) as well as other kinase domains regulate Src 
conformation and auto-inhibit Src activity
212, 213
. It has been shown that SH3 binding to 
integrin β3 tail in activated platelets disrupts fully intramolecular auto-inhibition of Src 
SH3 and increases Src activity
211, 214, 215
. Furthermore, full activation of c-Src requires 
ligand binding to β3 integrin, together with JAM-A dissociation from integrin αIIbβ330. 
To determinate how JAM-A suppresses c-Src activation initially described by Naik et al., 
they found the endogenous c-Src inhibitor CSK (C-terminal Src kinase) in the complex of 
integrin αIIbβ3–c-Src. Importantly, tyrosine-phosphorylated JAM-A recruits CSK 
binding to the complex, which in turn phosphorylates c-Src Y529 residue to constrain c-
Src activation178, 181. After ligand binding to integrin αIIbβ3, JAM-A and CSK dissociates 
from αIIbβ3, resulting in c-Src auto-phosphorylation for the transduction of outside-in 
signaling
211
.   
 
JAM-A was found tyrosine-phosphorylated in resting platelets (data shown in our paper), 
consistent with other studies179, 181, which gave the possibility of JAM-A interaction with 
its intracellular binding partner. In the present study, JAM-A was de-phosphorylated after 
platelet activated by Fg, which was inhibited by broad range protein tyrosine 
phosphatases (PTPs), indicating that PTPs are responsible for JAM-A de-phosphorylation. 
Furthermore, we found that JAM-A de-phosphorylation was blocked by specifically 
inhibiting the tyrosine phosphatase PTPN1 (PTP1B), but not PTPN6 and PTPN11 
(Figure 11A, B). Both in resting and activated platelets, JAM-A appeared to be associated 
with PTPN1 (Figure 12A), which can be recruited to integrin complex after integrin 
αIIbβ3 activation
187
. Additionally, Naik et al. have found that JAM-A is close proximity 
to the integrin αIIbβ3 complex. Therefore, PTPN1 is the phosphatase responsible for 
JAM-A de-phosphorylation after platelet activation, which might be a novel aspect of 
JAM-A regulating integrin outside-in signaling. However, the role and fate of de-
phosphorylated JAM-A after platelet activation remains to be elucidated. 
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Besides its interaction with integrin αIIbβ3, JAM-A regulates platelet activation through 
other mechanisms that are still unclear. In the present study, JAM-A deletion lowers the 
activation thresholds of integrin αIIbβ3 and elevates platelet activation state, which 
promotes vascular inflammation and atherosclerosis eventually. Integrin outside-in 
signaling can reinforce platelet aggregation by intracellular signaling cascade, which is 
triggered by platelet activation stimuli, such as ADP and thrombin, as a feedback loop of 
signaling pathways initiated by G protein-coupled receptors and integrins
216
. However, 
the mechanism of platelet–integrin αIIbβ3 regulating inflammatory response remains to 
be investigated. It has been shown that αIIbβ3 interaction with other integrins, such as 
GPVI, regulates platelet activation
217
. Non-specific blocking integrins, including αIIbβ3, 
showed long-term anti-inflammatory effects by suppressing the rise of circulating 
inflammatory markers, such as C-reactive protein and IL-6
218
. In the present study, 
tirofiban, as a specific inhibitor of αIIbβ3, suppressed platelet aggregation and adhesion 
to ECs. Conversely, it has been found that αIIbβ3 antagonists with active conformation 
inhibit inflammation by blocking platelet aggregation and reduce release of inflammatory 
mediators, such as soluble CD40 and CCL5
219, 220
. The different effects of integrin 
ligands might be dependent on their concentrations. Moreover, genetic αIIbβ3 in mice 
deficiency inhibited platelet adhesion to injured or atherosclerotic vessel wall and 
attenuated lesion formation
221
. Additionally, blocking αIIbβ3 using specific antibody or 
depletion of platelets using antiserum also reduced intimal hyperplasia, highlighting the 
pivotal role of platelet αIIbβ3 in vascular inflammation and remodeling
222
. A cohort study 
showed that a single nucleotide polymorphism (SNP) of αIIbβ3 increased risk of 
atherosclerotic plaque rupture223. In contrast to the augmenting the role of platelet αIIbβ3 
in atherosclerosis, Glanzman thrombasthenia patients with platelet αIIbβ3 deficiency did 
not show decreased atherosclerosis, despite intact functions of platelet adhesion and 
release of granule contents in response to adequate stimuli
224
. Together with the present 
study, JAM-A deficiency caused platelet hyperreactivity through up-regulated integrin 
αIIbβ3 signaling, which enhanced vascular inflammation and atherosclerosis.  Thus, 
JAM-A might inhibit platelet activity by suppressing integrin αIIbβ3 outside-in signaling 
to regulate vascular remodeling (Figure 23). 
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5.3 JAM-A deficient platelets propagate vascular inflammation 
Various substrates and soluble mediators activate platelets under blood shear stress, such 
as oxLDL. Activated platelets upregulate adhesion molecules, such as GPIb/IX/V, P-
selectin, CD40, and release pro-inflammatory stimuli deposited on vascular cell surfaces, 
such as CXCL4 and CCL5. These inflammatory mediators facilitate leukocyte 
recruitment and modulate the pathogenesis of vascular diseases. Additionally, platelets 
can trigger chemokine secretion from different cells of vascular wall, which in turn 
enhance platelet aggregation and adhesion. Thus, platelets have been considered as potent 
inflammatory cells that propagate inflammatory responses in vascular remodeling
225-227
.   
 Platelet adhesion to atherogenic vessel wall is enhanced by JAM-A 5.3.1
deficiency 
The hyperreactivity of JAM-A
–/–
apoe
–/–
 platelets was reflected by increased adhesion to 
endothelium. Consistent with previous studies, we chose the carotid bifurcation as the 
pro-atherogenic site to be perfused with whole blood and then quantified platelet 
adhesion on endothelium by TPLSM ex vivo. The data represent that trJAM-A deficiency 
increased platelet adhesion to the vessel wall, compared to JAM-A
+/+
apoe
–/–
 platelets, 
which was inhibited by blocking integrin αIIbβ3 (Figure 12). Furthermore, cultured 
endothelial cells were activated by TNFα and perfused with thrombin-activated platelets, 
showing that JAM-A deficiency dramatically boosted platelet binding to inflamed 
endothelium (Karshovska E, Zhao Z et al, Circ Res. 2015 Feb. 13; 116(4):587-99). 
Taken together, JAM-A deficiency augments platelet adhesion to inflammatory and 
atherogenic vessel wall.  
Platelet-endothelial cell interaction is mediated by adhesion molecules and some soluble 
mediators in plasma, including P-selectin to PSGL-1, GPIb to P-selectin or vWF, and 
integrin αIIbβ3 to endothelial ICAM-1. For example, integrin αIIbβ3 as an adhesion 
molecule mediates activated platelet arrest to ICAM-1 or αVβ3 on endothelium, through 
a bridge formed by Fg, vWF or fibronectin
94
.  Integrin αIIbβ links platelets to injured 
sites in vessels also by interaction with Fg and vWF88. Notably, blocking αIIbβ3 (by 
tirofiban) normalized the hyperadhesion of JAM-A
–/–
 platelets, indicating that αIIbβ3 is 
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important for platelet adhesion, but it did not significantly affect JAM-A
+/+
apoe
–/–
 
platelets adhesion (Figure 12C, D), suggesting that other adhesion molecules are also 
involved in platelet-endothelial interaction, such as GPIbα94, 228.  
Dysregulation of platelet-endothelial cell interaction was always found at atherosclerotic 
predilection sites, such as bifurcation of the carotid artery, where plaques develop earlier 
than at other sites of vessel wall9. JAM-A deficiency enhanced this process, as JAM-A–/– 
platelet adhesion to atherogenic vessel wall and inflamed endothelium was increased, 
which would further promote the pathophysiology of vascular remodeling
228, 229
. 
Adherent platelets then activate endothelial cells to express various inflammatory 
mediators, such as IL-1β, CCL2, macrophage inflammatory protein-1α and ICAM-1
230
. 
In addition, activated platelets upregulate CD40 ligands, which initiate endothelial 
inflammation through cognate receptor CD40 and stimulate endothelial cells to express 
inflammatory mediators
100, 185, 231, 232
. The inflamed endothelium generates crucial signals 
for leukocyte recruitment and extravasation at sites of vascular injury or initiating an 
inflammatory response of previously intact endothelium
100, 230
. Interestingly, CD40L on 
activated platelets can bind to αIIbβ3 triggering outside-in signaling in inflammatory 
process
231, 233, 234
, which might be enhanced by JAM-A absence. Conversely, endothelial 
cells also can stimulate platelets during inflammatory progress. For example, ADAM15 
expressed on endothelium can serve as an adhesion receptor for platelets via integrin 
αIIbβ3 binding, which in turn leads to platelet activation as well as secretion and 
promotes thrombus formation in cardiovascular disease235. Whether endothelium in 
trJAM-A
–/–
apoe
–/– 
mice augmented platelets activation via integrin αIIbβ3 in our model 
remains to be demonstrated. Briefly, JAM-A
–/–
apoe
–/– 
platelet adhesion to endothelial 
cells significantly increased, compared to JAM-A
+/+
apoe
–/–
 platelets (Figure 12), which 
might be responsible for increased atherosclerotic plaques in trJAM-A
–/–
apoe
–/– 
mice. 
Direct interactions of platelets with endothelial cells results in up-regulation of 
inflammatory mediators and exacerbates vascular inflammation. 
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 Plasma chemokine concentrations increase due to platelet–JAM-A 5.3.2
deficiency 
Upon activation, platelets release several pro-inflammatory mediators including 
chemokines, which can modulate endothelial cell activation and leukocytes recruitment 
to inflammatory sites in the vasculature. In trJAM-A
–/–
apoe
–/–
 mice, we found diminished 
granular staining of chemokines CXCL4 and CCL5 in platelets, which were paralleled 
with increased levels in plasma during the time course of HFD administration (Figure 13). 
These results suggest that increased circulating chemokines might be released from JAM-
A
–/–
apoe
–/–
 platelets during the time course of HFD, hinting JAM-A
–/–
apoe
–/–
 platelets at 
decreased activation threshold of granular release. More chemokines would be deposited 
onto the vessel wall in trJAM-A
–/–
apoe
–/–
 mice and lead to increased recruitment of 
leukocytes into plaques. Actually, lots of chemokines have been found in early and 
advanced atherosclerotic lesions, suggesting that persistent activation of platelets and 
their secretion contribute to the evolution of cardiovascular diseases
9, 185, 236, 237
.  
Leukocytes and endothelial cells are the first cells to be exposed to the chemokines 
released from platelets. Deposition of chemokines from platelets to their cognate 
receptors on vascular cell surfaces links platelet activation to the recruitment of immune 
cells and exacerbates vascular diseases88, 227, 238. JAM-A deficiency increased plasma 
levels of CCL5 and CXCL4, which can be delivered to endothelium and 
leukocytes/monocytes. The effective deposition of chemokines on cell membrane is 
facilitated by direct interactions of cells or by transfer from platelet microparticles to the 
vessel wall
60, 239
. As a result, chemokines binding to chemokine receptors (GPCRs) or 
GAGs on vascular cell surfaces leads to their immobilization and gradients formation for 
leukocytes recruitment
122
. Thus, we predicted that plasma levels of CCL5 and CXCL4 
might enhance leukocytes recruitment into plaques of trJAM-A
–/–
apoe
–/–
 mice. 
CXCL4 is stored predominantly within platelets and released upon platelet activation, 
which can be localized in atherosclerotic lesions and correlated with lesion severity as 
well as symptomatic atherosclerosis
129
. CXCL4 is known to promote atherosclerosis in 
CXCL4-deficient mice, which showed significant reduction of atherosclerotic plaques in 
the aorta
240
. Under conditions of arterial injury or possible endothelial dysfunction with 
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platelets attachment, CXCL4 is transferred rapidly into the media
241
. Then, CXCL4 
stimulates SMCs into an inflammatory phenotype, such as decline of differentiation 
markers, increase of cytokine production and cell proliferation, which promotes lesion 
formation after partial ligation of carotid artery
242
. In this study, we suggested that the 
increased plasma CXCL4 might contribute to the increased accumulation of SMCs at 
early-stage of plaque formation in trJAM-A
–/–
apeo
–/– 
mice. Although lacking of a 
chemotactic activity for neutrophils
243
 and monocytes
130
, CXCL4 initiates a signal 
transduction cascade leading to a broad spectrum of functions. On endothelium, CXCL4 
binds to endothelial cells via cell surface GAGs, promoting leukocyte adhesion by 
increasing expression of adhesion molecules. In the presence of appropriate costimuli, 
such as TNF-α, CXCL4 can activate neutrophils, cause exocytosis and promote adhesion 
to endothelium
125, 128, 244
. On monocytes, CXCL4 has a number of different effects, 
including anti-apoptosis effect and facilitating macrophage differentiation during 
inflammatory process
131
, increasing monocyte phagocytosis
130
 and inducing cytokines 
secretion
134
. For example, CXCL4 triggers many signaling pathways in monocyte 
survival and cytokine expression, controlled by Erk and JNK
134
.  
CCL5 has been found to cause the selective migration of human blood monocytes and T 
cells via CCR5 and CCR1 receptors
138
. Immobilized and presented on activated 
endothelium, CCL5 enhances monocyte recruitment
81
 and contributes to inflammatory 
response in vascular remodeling
88
. Conversely, inhibition of CCL5 results in decreased 
lesion size, both in atherosclerosis and vascular injury38, 60, 81, 149, 245. Thus, the present 
data indicates that increased levels of CCL5 due to platelet–specific JAM-A deficiency 
propagated vascular remodeling. Plasma CCL5 concentration in trJAM-A
–/–
apoe
–/–
 mice 
was significantly increased during 2 weeks or 6 weeks HFD feeding (Figure 13D). 
Notably, at early stage, we found that the abundance of macrophages and T cells in 
plaques of trJAM-A–/–apoe–/– mice significantly increased, compared to JAM-A+/+apoe–/– 
mice, which might be partly caused by the dramatically increased CCL5 in plasma 
enhancing leukocytes infiltration. However, at a more advanced stage of atherosclerosis, 
there was no significant difference of plaque size in aortic root and leukocyte contents in 
plaques between trJAM-A
–/–
apoe
–/–
 mice and trJAM-A
+/+
apoe
–/–
 mice, paralleled with no 
difference of plasma CCL5. Thus, the role of JAM-A–deficient platelets at advanced 
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stages of atherosclerosis was limited, which might be reflected by the decreased plasma 
CCL5 concentration.  
Interestingly, CCL5 and CXCL4 concentrations in trJAM-A
–/–
apoe
–/–
 mice showed 
different trends in the progress of atherosclerosis. Plasma CXCL4 levels in trJAM-A–/–
apoe
–/–
 mice increased continuously during HFD, different with the increased plasma 
levels of CCL5 only at early stages (Figure 13). It indicates that chemokines are released 
from activated platelets selectively according to different stages of inflammatory disease. 
In fact, several studies have reported differential, stimulus-specific packaging and release 
of platelet granules246, 247, which could potentially enable platelets to specifically release 
inflammatory granules
248
. For example, Italiano et al. reported differential release of the 
angiogenic factor vascular endothelial growth factor and endostatin after targeted 
stimulation of PAR1 and PAR4, respectively
100
. CXCL4 and CCL5 can interact and form 
a heterodimer. This complex in atherosclerosis has a more potent effect on monocyte 
arrest to stimulated endothelium than each chemokine alone133. Disrupting the 
CXCL4/CCL5 interactions by using a peptide inhibitor decreases monocyte recruitment 
and leads to a reduction of atherosclerotic lesions. Taken together, these studies 
demonstrate a synergic effect on monocyte recruitment by the CXCL4/CCL5 heterodimer 
complex
249
. We predicate that the increased plasma levels of CXCL4 and CCL5 in 
trJAM-A–/–apoe–/– mice might form more CXCL4/CCL5 complexes, which in turn 
reinforce leukocytes recruitment. 
 Leukocyte recruitment is augmented due to JAM-A–deficient platelets  5.3.3
Beside release of increased chemokines driving leukocytes recruitment, JAM-A–deficient
 
platelets also facilitated leukocytes interactions with vessel wall. In vitro and ex vivo 
experiments, we found that JAM-A–deficient  platelets showed significantly enhanced 
adhesion, paralleled with increased co-localization of leukocytes on the pro-
atherosclerotic and inflamed endothelium. The augmented firm arrest of monocytes was 
further demonstrated in vivo experiments (Karshovska E, Zhao Z et al, Circ Res. 2015 
Feb. 13; 116(4):587-99), which could be explained by previous studies that platelets 
‘carpet’ the endothelium during inflammation to form a ‘physical bridge’ via P-selectin-
dependent mechanisms to promote leukocytes recruitment to endothelium
250-252
. The 
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mechanisms of platelet adhesion to endothelium for leukocyte recruitment have been 
investigated. For example, plenty of P-selectin and other adhesion molecules are up-
regulated on the platelet membrane after activation, covering inflamed endothelium. 
Presented selectins promote not only the tethering and rolling of PSGL-1-expressing 
leukocytes, but also of additional platelets, thus amplifying the recruitment
253-255
. In fact, 
platelet-derived P-selectin, not endothelial P-selectin, has been identified as predominant 
ligand for leukocyte recruitment during the inflammatory process
256-258
. Blocking platelet 
interactions with endothelium and leukocytes by removal of platelet P-selectin effectively 
delays the onset of atherosclerotic disease
259
 and reduces neointimal formation after 
vascular injury
260
. The following step is firm adhesion and activation of leukocytes via 
Mac-1 to platelet GPIbα or to integrin αIIbβ3 in a fibrinogen-dependent manner, which in 
turn triggers release of pro-inflammatory mediators from adherent platelets, including 
CXCL4 and CCL5261. Thus, the up-regulated activity of platelet–integrin αIIbβ3 due to 
JAM-A deficiency could increase the interaction of platelets with leukocytes, resulting in 
exacerbated recruitment of leukocytes. 
Additionally, JAM-A-deficient platelets showed significantly increased aggregation to 
leukocytes, as more complexes of platelet-monocyte and platelet-neutrophil in blood, 
which was abolished by blocking platelet–integrin αIIbβ3 (Figure 14).  The increased 
aggregation of leukocytes with JAM-A–deficient platelets could promote leukocyte 
rolling and arrest
253-255
. Previous studies have shown that these complexes are relevant 
with inflammatory diseases and cardiovascular diseases262-264. Platelet interaction with 
leukocytes primarily occurs in a P-selectin/PSGL-1 dependent manner, and is 
bidirectional. Activated platelets induce activation of transcription factor NF-kB, 
leukocyte integrins and related gene products in leukocytes
103, 116, 265
, which amplify 
vascular inflammation. We found that platelet-neutrophil complexes in the blood of 
trJAM-A–/–apoe–/– mice were dramatically increased. In previous studies, these 
complexes may be short-lived, but induce signaling to activate neutrophil integrins, 
promote the degranulation, enhance phagocytosis
266, 267
, and boost neutrophil 
transmigration across endothelium
268-270
.  Additionally, platelets prime neutrophils for 
efficient adhesion to endothelium via the up-regulation of integrins, such as Mac-1 and 
enhance responsiveness to chemokines124, 125, which are required for the recruitment of 
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neutrophils to inflamed tissue. Activation of the integrin Mac-1 is known to be critical for 
mediating neutrophil adhesion and migration, involving the protein kinase C zeta 
(PKCζ)102. Beside recruitment promotion, activated platelets have been shown to inhibit 
neutrophil apoptosis
271
, which may  further enhance inflammatory roles of neutrophils in 
vascular disease. Remarkably, it has been clearly found that the interaction of activated 
platelets with neutrophils in circulation as well as on vessel wall, by the dynamic 
reorganization of neutrophil domains and receptors, initiates inflammatory responses
272
. 
Platelet-monocyte aggregates have been shown to be an early predictor for cardiovascular 
events
105
. The monocyte–platelet complexes form more abundantly, more rapidly and 
more stable than other platelet-leukocyte complexes. Despite P-selectin–dependent 
adhesion of platelets to monocytes, it has been inferred that PSGL-1/P-selectin 
interaction promotes the binding of monocyte VLA-4 to vascular cell adhesion molecule-
1 (VCAM-1) during the sequential cascade that regulates monocyte trafficking to 
inflammatory and atherosclerotic lesion
273
. In addition, platelet-derived pro-inflammatory 
mediators deposited on the endothelium causes increased monocyte arrest, mediated by 
integrin activation38, 60, 81. Interaction of monocytes with platelets increases the adhesive 
properties and recruitment of monocytes towards inflamed or atherosclerotic 
endothelium
111, 274, 275
, which could explain our observations that more JAM-A
–/–
 platelet-
monocyte complexes in blood were paralleled with enhanced monocytes adhesion to the 
endothelium in vivo experiment. Platelet-activated monocytes are shifted to a pro-
inflammatory phenotype, are recruited and transmigrate more efficiently at sites of 
inflammation, and tend to differentiate towards a dendritic cell type
265
. The interaction of 
platelets and pro-inflammatory macrophages has also been demonstrated to enhance 
macrophage activation
276
. Thus, crosstalk in monocyte–platelet complexes promotes 
monocyte phenotypic changes as well as extravasation, eventually promoting foam cell 
formation277, which might be responsible for the increased number of Mac2+ 
macrophages in plaques of trJAM-A
–/–
apoe
–/– 
mice (Figure 17A).  
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5.4 Platelet–JAM-A deficiency promotes vascular remodeling 
 Atherosclerosis is accelerated due to platelet–JAM-A deficiency 5.4.1
Platelets can also initiate and propagate vascular inflammation, which may lead to the 
development of atherosclerotic plaques
232, 278
.  In the present study, we found that JAM-A 
deficient platelets markedly exacerbated atherosclerosis in aortas of trJAM-A
–/–
apoe
–/–
 
mice, compared to trJAM-A+/+apoe–/– mice, fed time-course HFD (2 weeks, 6 weeks and 
12 weeks), indicating that platelet-specific JAM-A-deficiency increased atherosclerotic 
burden in mice vasculature. Interestingly, plaque sizes in aortic roots of trJAM-A
–/–
apoe
–
/–
 mice fed 2 weeks HFD showed significant increase, compared to trJAM-A
–/–
apoe
–/–
 
mice, but not after 6 weeks and 12 weeks HFD (Figure 15, 16). These data indicate that 
the effects of JAM-A–/– platelets might decline during the progress of atherosclerosis in 
aortic root. The detailed roles of platelets in different stages of plaque formation are just 
emerging. Previous studies have implicated the role of platelets and their secretion 
products particularly in early phases of plaque development
9, 185, 236
. In early stages, the 
number of adherent platelets to endothelium consistently increase in the progress of 
atherosclerosis, which precede the development of manifest atherosclerotic lesions, as 
platelets  might initiate inflammatory responses of endothelium
185, 232
 and then recruit 
leukocytes to atherosclerotic predilection sites, such as the bifurcation of the carotid 
artery, where plaques develop
9
. Adhesion of activated platelets via P-selectin, GPIbα, and 
αIIbβ3 to endothelium induces endothelial expression of adhesion molecules, such as 
VCAM-1, E-selectin, chemokines (eg, CCL2, CXCL4 and CCL5), and matrix 
metalloproteinases (MMP-1, -2, and -9) 
9, 60, 81, 98, 227, 231, 233
. These factors triggered by 
activated platelets facilitate leukocyte infiltration into the vessel wall, thus initiating and 
accelerating atherosclerotic plaque formation. However, we found that the numbers of 
Mac2
+
 macrophages and CD3
+
 T cells were significantly increased in plaques of JAM-A
–
/–apoe–/– mice, paralleled with augmented SMCs accumulation, only at early-stage lesion 
(Figure 17). There was no significant difference of these inflammatory cell numbers in 
advanced plaques between trJAM-A
–/–
apoe
–/–
 mice and trJAM-A
+/+
apoe
–/–
 mice (Figure 
18), implying that JAM-A–deficient platelet-related effects on vascular inflammation 
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might become secondary. Other cell types, not affected by our model of platelet-specific 
deletion, might gain prominence as atherosclerosis progression.  
Yet the crucial roles of platelets in advanced stages of atherosclerosis were also 
demonstrated by previous studies. For example, inhibition of GPIb using a blocking 
antibody in apoe
–/–
 mice dramatically reduced plaque formation after 18 weeks of HFD
9
. 
Additionally, repeated infusion of activated platelets exacerbated atherosclerosis185 and 
integrin αIIbβ3 deficiency caused a significant reduction in plaque burden particularly 
after 12 weeks of HFD
221
. In this respect, although there was no significant difference of 
plaque formation and leukocyte infiltration in aortic roots after 12 weeks of HFD (Figure 
18), there was still marked increased plasma chemokine levels (CXCL4 and CCL5) and 
plaque burden in vasculature of trJAM-A–/–apoe–/– mice (Figure 13, 15). Thus, we 
hypothesize that platelet hyperreactivity, though present throughout the entire course of 
our study, might have the most pronounced effects on initial events of atherosclerosis, 
such as the induction of endothelial dysfunction, crosstalk with leukocytes in blood and 
propagation of leukocyte recruitment by increased plasma chemokine levels, but the 
effects of platelet-specific JAM-A–deficiency declined at advanced plaque formation, 
particularly in the aortic roots. The effects of JAM-A–deficient platelets at different 
stages of atherosclerotic plaque formation as well as at different locations of vasculature 
need to be further clarified. 
 
Taken together, platelet–JAM-A suppresses the activity of Integrin αIIbβ3, which is 
functional in inflammatory platelet functions and the development of atherosclerosis, 
consistent with previous studies
9, 99, 221
. However, the anti- or pro-atherosclerotic roles of 
αIIbβ3 are still controversial as patients with genetic deficiency of αIIbβ3 not protected 
from atherosclerosis
224
. Our results are limited to explain the role of integrin αIIbβ3 in 
atherosclerotic formation directly. Atherogenic effects of blocking platelet–integrin 
αIIbβ3 in JAM-A
–/–
apeo
–/–
 mice need further investigation.  
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 Platelet–JAM-A inhibits neointimal formation at early stage 5.4.2
The high incidence rate of restenosis is around 25-40% after PTA and stenting treatment 
in patients with obstructive atherosclerosis
13, 15
, which is caused by neointimal formation. 
The neointimal lesions consist mainly of SMCs and inflammatory leukocytes
279
. Vascular 
injury causes endothelial denudation and exposure of extracellular matrix. Following 
acute vascular injury, pathophysiological processes occur rapidly, which include platelet 
adhesion, thrombus formation, leukocytes infiltration
16
, as well as SMCs proliferation, 
migration and secretion of extracellular matrix
17
. Platelets, as the first adherent cells on 
the injured vessel wall, play a pivotal role in initiating the repair process and driving 
neointimal formation38.  We found that JAM-A deficiency increased platelet adhesion on 
endothelium-denudated vessel wall, which might promote lesion formation at early stage 
of the arterial repair progress. Lots of mechanisms are involved, such as enhanced 
interactions of JAM-A–deficient platelets with leukocytes and injured vessel wall, 
increased release of chemokines and augmented recruitment of leukocytes. Furthermore, 
it has been found that platelet–JAM-A mediates recruitment of progenitor cells to injured 
vessel wall, which promotes re-endothelialization
164
. Nevertheless, the mechanisms 
responsible for JAM-A–/–apoe–/– platelet–mediated neointimal formation have not been 
sufficiently elucidated. 
5.4.2.1 JAM-A deficiency increases platelets adhesion on the injured vessel wall 
After endothelium denuded, the extracellular matrix is exposed to the blood flow, which 
leads to platelet adhesion. We used HPLSM to image platelet adhesion on injured carotid 
artery ex vivo and calculated adherent platelet volume on vessel wall using the software 
Lecia Application Suite X. The data shows that the adhesion of JAM-A–deficient platelets 
to injured vessel wall after operation 1 hour was significantly increased, compared to 
control group (Figure 19).  
Platelet adhesion to the injured arterial wall is mediated by several cellular adhesion 
molecules with sub-endothelial extracellular matrix containing adhesive molecules, such 
as collagen, vWF and fibrinogen
280
. Under high sheer condition of blood flow, platelets 
adhesion is initiated by platelet vWF receptor GPIb/V/IX and collagen receptor integrin 
α2β1 as well as GPVI194, 281. Other adhesive proteins in extracellular matrix, such as 
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fibronectin, thrombospondin, laminin and vitronectin, also mediate platelets interaction 
with the endothelial denudated vessel wall. The interaction of these adhesion molecules 
results in the formation of platelet layer covering on the injured vessel wall. Especially, 
the signal transduction of GPVI activates FcRγ chain, which in turn triggers inside-out 
signaling to activate integrin αIIbβ3 or α2β1 for platelet firm adhesion
195, 282, 283
. We have 
demonstrated that JAM-A deficiency decreased the thresholds of integrin αIIbβ3 
activation, which might contribute to the enhanced integrin αIIbβ3–fibrinogen interaction. 
Thus, platelet JAM-A might suppress platelet adhesion to injured arterial wall via 
regulating αIIbβ3 activation. Subsequently, adherent platelets get activation and recruit 
more platelets, which cause platelet shape change and degranulation of fibrinogen, 
ADP/ATP as well as and thromboxane A2 (TxA2). These mediators as positive-feedback 
of platelet activation amplify the initial signals to result in integrin αIIbβ3-mediated 
aggregation of platelets. In the present ex vivo experiment, JAM-A as a negative regulator 
of integrin αIIbβ3 attenuates platelet aggregation on the endothelium– denudated vessel 
wall (Figure 19). 
5.4.2.2 trJAM-A deficiency exacerbate neointimal formation at early stage 
The functions of JAM-A in vascular remodeling have been characterized. For example, 
somatic deficiency of JAM-A in mice dramatically suppressed neointimal formation and 
leukocytes infiltration into the lesion
39
. In addition, the cell–specific roles of JAM-A in 
atherosclerosis have been demonstrated recently40. Furthermore, JAM-A deficient caused 
platelet hyperreactivity and promoted atherosclerosis, especially at early stage. Upon our 
previous studies, the same phenomenon was observed in neointimal formation. We found 
that platelet JAM-A deficiency increased neotintimal formation in carotid artery after 
wire-injury 2 weeks, but this effect was diminished after 4 weeks (Figure 20, 19). These 
data suggest that platelet hyperreactivtiy due to JAM-A absence initiates and propagates 
vascular remodeling, obviously at early stage. In later stages, these platelet-related 
activities might become secondary and other cell types might gain prominence. Similar 
with neutrophil, it was found to preferentially invade early-stage lesions, whereas the 
influence declines at advanced phases of vascular remodeling
236
. Acute vascular injury 
cause repair progress and inflammatory response, which is characterized by leukocytes 
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infiltration into the injured wall and SMCs migration as well as proliferation. In the 
present study, we found that platelet–JAM-A deficiency significantly increased the 
number of CD3+ T cells in advanced neointimal lesion, but the data of macrophages did 
not show marked difference between trJAM-A
+/+
apoe
–/–
 and trJAM-A
–/–
apoe
–/–
 mice 
(Figure 22). These data indicate that JAM-A–deficient platelet mildly augmented 
inflammatory responses at advanced stage of vascular repair after acute injury, but the 
mechanism of platelet–JAM-A regulating vascular repair in early stages remains to be 
investigated.  
Previous studies have shown that the mechanisms of activated platelets aggregating 
vascular inflammation and facilitate vascular remodeling
60
. In our mice model, we found 
the hyperreactivity of JAM-A–deficient platelets promoted atherosclerosis and neointimal 
formation, which is limited at advanced stage. In the process of vascular repair, the 
recruitment of leukocytes drives pathogenesis of neointimal formation
284
. Nevertheless, 
Platelets via leukocyte adhesion receptors or directly bridging between leukocytes and 
the vessel wall play critical roles for leukocyte infiltration
285, 286
. Thus, increased 
interactions of JAM-A–deficient platelets with leukocytes in blood flow (Figure 14) as 
well as endothelium-denudated vessel wall (Figure 19) would improve acute 
inflammatory responses. Furthermore, JAM-A deficiency increased platelet 
degranulation of chemoattractants, such as the elevated plasma level of CCL5 and 
CXCL4 (Figure 13). Deposition of chemokines from platelets to their cognate receptors 
on vascular cell surfaces links platelet activation to the recruitment of immune cells and 
exacerbates vascular diseases
88, 227, 238
.  These chemokines are also localized on the vessel 
wall, further enhancing inflammatory responses
37, 38
. These mechanisms might explain 
the increased neointimal formation in trJAM-A
–/–
apoe
–/– 
mice at ealy stage. At later 
stages, re-endothelialization might diminish platelet adhesion on vessel wall, thus 
suppressing the effects of JAM-A–deficient platelets on neointimal formation. However, 
the role of platelet–JAM-A in neointimal formation after arterial injury remains to be 
elucidated. 
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6 Summary 
Platelets play an essential role in hemostasis and also act as immune cells regulating 
inflammation. The deficiency of platelet function suppresses atherosclerosis in 
hyperlipidemic mice
60, 77
. In the present study, platelet hyperreactivity due to JAM-A 
absence promoted vascular remodeling, particularly in early phases. 
 
Although plenty of mechanisms are responsible for platelet activation, little is known 
about the signaling pathways that negatively regulate platelet function. Recently, JAM-A 
was found to inhibit platelet outside-in signaling through integrin αIIbβ3. Consistent with 
previous studies (Naik et al., Blood 2013), we also report that JAM-A suppresses platelet 
reactivity through down-regulating c-Src activity in integrin αIIbβ3 outside-in signaling. 
 
Specific deletion of JAM-A in platelets led to an enhanced response to various agonists, 
such as ADP or thrombin. As a result, interactions of JAM-A–deficient platelets with 
leukocytes as well as with inflamed vascular endothelium are increased. Remarkably, 
tirofiban as an inhibitor of integrin αIIbβ3 normalized the hyperreactivity of JAM-A–
deficient platelets. Furthermore, increased plasma levels of chemokines (CCL5 and 
CXCL4) and an increased recruitment of leukocytes was found in propagated plaques of 
trJAM-A–/–apoe–/– mice. Taken together, deletion of JAM-A caused a gain-of-function in 
platelets with lower activation thresholds. This promoted vascular inflammation and 
increased plaque formation, particularly in early stages. 
 
JAM-A–deficient platelets gained an increased aggregation on endothelium-denudated 
vessel wall, which might accelerate neoinitmal formation at early stage after vascular 
injury, but not at advanced stages. The detailed mechanisms of JAM-A–deficient 
platelets facilitating neointimal formation remain to be investigated. 
 
Taken together, Hyperreactivity of JAM-A–deficient platelets aggravates vascular 
inflammation and remodeling in hyperlipidemic mice, particularly at early stages. This 
highlights the detrimental role of activated platelets in preclinical phases of 
cardiovascular disease. 
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